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Summary 
Health care professionals are responsible to ensure safe dispensing and use of drug 
regimens involving the use of drug combinations that may interact and cause serious 
adverse events. In the last 40 years an enormous amount of data on drug 
interactions has been published. But, although potential drug interactions are 
probably common only few of them manifest serious adverse events and often only in 
predisposed patients. Therefore, health care professionals feel inundated with hints 
for potential drug interactions of questionable clinical significance provided by their 
drug interactions information sources. Computerised alerts systems enable important 
assistance but their performance is not satisfying.  
Simply knowing that two drugs may interact does not offer enough information to 
health care professional to devise a plan to reduce risk of an adverse outcome. The 
risk of most drug interactions can be minimised by an accurate management (e.g. by 
dose adjustment, spacing of dosing times and close monitoring of the therapy) and 
thus, drug combinations do not have to be avoided. Therefore, drug interaction 
information sources should directly provide guidelines about the manageability of a 
drug interaction. 
The present thesis aimed to focus on four different aspects of the management of 
potential drug interactions in hospitalised and ambulatory patients: A) to determine 
the influence of patient-related risk factors on the development of an adverse 
outcome, B) to assess the prevalence and patient knowledge of potential drug 
interactions with over-the-counter (OTC) drugs used for self-medication, C) to assess 
preoccupation with potential drug interactions, perception of quality of drug 
interaction information sources, information needs, and how their requirements relate 
to those expressed by general practitioners, and D) to observe on site the 
management of potential drug interactions in daily community pharmacy practice. 
 
Drugs have been recognised as a primary or contributing cause of hyperkalaemia, 
especially when administered to patients with underlying risk factors. The objective of 
project A was to analyze the influence of known risk factors on the velocity to 
develop hyperkalaemia in 551 hospitalised patients. Compared to the drug treatment 
at entry, during hospitalisation significantly more patients were treated with drugs 
associated with hyperkalaemia such as heparins, angiotensin converting enzyme 
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inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), potassium supplements, 
potassium-sparing diuretics, and/or NSAIDs or COX-2 selective inhibitors. Risk 
factors associated with a high velocity to develop hyperkalaemia were in descending 
order: use of potassium supplements, severe renal impairment, use of potassium-
sparing diuretics, use of ACEIs or ARBs, and diabetes mellitus. The velocity to 
develop hyperkalaemia significantly increased in patients with ≥2 of such risk factors. 
Dose-effects could be found for potassium supplements and potassium sparing 
diuretics, but not for ACEIs or ARBs. In contrast, use of kaliuretics (loop diuretics or 
thiazides) was associated with a decreased velocity to develop hyperkalaemia.  
The results of this study have shown that patients with multiple risk factors should be 
closely monitored and a rapid change in laboratory values should alert health care 
providers to adequate actions. 
 
Project B focussed on selected potential drug interactions of different clinical 
relevance between prescription only medicines (POMs) and OTC drugs pharmacy 
customers purchased for self-medication. In community pharmacies potential drug 
interactions with self-medication arise mainly in two situations: First, if an OTC drug is 
purchased by a passer-by customer whose prescribed drug therapy is not known, or 
second, if a POM or an OTC drug is requested by a regular customer whose 
prescribed drug therapy is usually recorded. Both customer groups were checked for 
potential drug interactions. Of 1183 observed passer-by customers, 164 (14.4%) 
purchased at least one of selected OTC drugs with risk for potential drug interactions. 
Out of them 102 (62.2%) were interviewed: 43 (42.2%) mentioned taking prescribed 
drugs, and 3 of them were exposed to potential drug interactions of moderate 
severity.  
Out of 592 regular customers using at least one selected drug with a risk for potential 
drug interactions, 434 (73.3%) could be interviewed. Of them 69 (15.9%) were 
exposed to a potential drug interaction between purchased OTC drug for self-
medication and their POM. Furthermore, 116 (26.7%) regular customers were 
exposed to potential drug interactions within their prescribed drugs and in 28 (6.5%) 
multiple (≥ 2) potential drug interactions were found. Out of 434 regular customers 
203 (46.8%) were aware of potential drug interactions between their POM and OTC 
drugs. Of them 96 (47.3%) were informed by their prescribing physician and 52 
(25.6%) by their community pharmacist. Awareness of potential drug interaction was 
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significantly associated with the age of customers and the potential severity of drug 
interactions.  
Thus, the results of this study support efforts to increase awareness of potential drug 
interactions with OTC drugs. Although community pharmacies are adequately 
equipped with computerised drug interaction surveillance systems this is often not 
applied to self-medication. Vigilance for potential interactions of all drugs, including 
those sold over the counter, should be increased.  
 
Project C aimed to analyze the current drug interaction management in Swiss 
community pharmacies with a particular focus on electronic systems and to compare 
the results with those gathered among German general practitioners in a recent 
survey. A postal questionnaire was randomly sent to 500 community pharmacies of 
the German part of Switzerland. The response rate was 57.4%. Only 24.7% 
pharmacists reported to be confronted less than daily with potential drug interactions. 
Use of computer software to identify potential drug interactions was widespread in 
community pharmacies (90.2%) and the software was the primary source of 
information (81.2 ± 29.6%). The quality of the interaction software was judged 
sensitive (identifying all dangerous interactions) by 80.5 ± 21.5% but specific 
(identifying only relevant interactions) by only 38.3 ± 32%. Pharmacists declared a 
low override rate (14%) of drug interaction alerts although unjustified alerts were 
reported by 60.6 ± 33.1%. In contrast to general practitioners pharmacists opted less 
often for information on the mechanism of the interaction and more frequently for 
details for dose adjustment. Both groups complained about deficient information on 
non-interacting alternatives. The information needs of community pharmacists 
differed considerably from general practitioners.  
Substantial improvement of drug interaction software systems is thus required at 
least in two important aspects: the suppression of inappropriate alerts and the 
tailoring to the needs of the user. 
 
Drug interaction alert systems are commonly used in community pharmacies. They 
intend to ensure safe medication dispensing and use. But, pharmacists are inundated 
with alerts and override is possible. In project D on-site practice of community 
pharmacies was observed and the nature and management of drug interaction alerts 
were analysed. During two days 15 researchers assessed in 15 different pharmacies 
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data of 600 regular customers with multiple drug therapy (≥ 2 drugs) and interviewed 
the responsible pharmacists about the management actions in consequence of drug 
interaction alerts. The median frequency of drug interaction alerts increased from 0.5 
to 40 to 76 depending on the settings of the 15 community pharmacies’ computer 
systems to flag only severe (N=4), severe and moderate (N=6) or severe, moderate 
and minor (N=5) potential drug interactions. Because of these settings out of 787 
potential drug interactions detected on new or repeated prescriptions 277 (35.2%) 
were technically overridden by computer systems. Only 256 (32.5%) of 787 potential 
drug interactions emerged from a new prescription. The drug interaction alert 
systems produced 656 alerts of which 146 (22.3%) were invalid because of multiple 
alerts for the same interaction or alerts for combinations of which one drug was no 
longer taken. Of the 510 remaining relevant drug interaction alerts 289 (56.7%) were 
overridden by community pharmacists without any evaluation. The attendance of the 
patients by the pharmacists themselves was associated with a lower override of 
alerts. The sum of technical and pharmacist’s override results in a rate of 71.9%. Of 
the remaining 211 potential drug interactions 87 (41.2%) were analysed trough 
consultation of literature, a physician or the patient himself and of them 55 (63.2%) 
resulted in an intervention (close monitoring, adjustment of dose or ingestion time, 
stop of therapy, or alternative therapy). Determinants associated with the analysis of 
drug interaction alerts were the potential high severity (severe or moderate) and the 
alert flagged for the first time.  
As long as no sophisticated solutions are available it is important to avoid override of 
clinically relevant potential drug interactions. All of the 10 potential drug interactions 
classified as severe were detected and adequately managed. Therefore, 
classification of potential drug interactions is a very strong determinant for detection. 
Two conclusions are drawn from this study: Firstly, a focus on first-time alerts 
generated by new prescriptions and the elimination of invalid alerts would result in a 
substantial improvement in the specificity of drug interaction alert systems, and 
secondly, the claim to reduce their sensitivity by filtering drug interaction of moderate 
or minor severity might be reduced.  
Summary 
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In conclusion this thesis shows that: 
 
• Patients with risk factors (renal impairment, diabetes mellitus) should be 
closely monitored when adding combinations of risk drugs (potassium 
supplement, potassium-sparing diuretics, ACEI or ARB) for hyperkalaemia 
and a rapid change in laboratory values should alert health care providers to 
action by identifying and possibly removing risk drugs.  
 
• Potential drug interactions between POM and OTC drugs for self-medication 
are widespread. Efforts for an improved vigilance and an increase of patient 
awareness are needed. New approaches to assess self-medication like 
account cards to assess regular customers OTC drugs can be promising. 
 
• Computer-assisted drug interaction surveillance in community pharmacies 
lacks sensitivity and specificity while producing a high rate of invalid alerts. 
The information needs of community pharmacies differed considerably 
compared to those of general practitioners. Hence, substantial improvement 
of drug interaction software systems is required at least in two important 
aspects, the suppression of inappropriate alerts and the tailoring to the needs 
of the user. 
 
• Pharmacists override many drug interaction alerts without any evaluation 
either by ignoring them or by setting their systems to flag only potential drug 
interactions of high severity. They are sensitised to analyse first-time alerts 
and potential drug interactions of high severity. The results of Project D show 
that focusing on new prescriptions would significantly reduce the number of 
alerts. Therefore, substantial improvement by new sophisticated options 
implemented in computer-assisted drug interaction alert systems is required.  
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1  General introduction 
A multiplicity of outcomes is possible when people use drugs. Most commonly the 
patient benefits from drug therapy; however, adverse events, ranging from minor side 
effects to death, may occur. One of the consequences of multiple drug use is the risk 
of one drug influencing the activity, the availability or the effect of a second drug. This 
so-called drug interaction can be desired1 or result in adverse effects like reduced 
effectiveness or increased toxicity of the involved drugs.2 There are a number of 
mechanisms by which drugs interact with each other, and most of them can be 
divided in two general categories: pharmacokinetic and pharmacodynamic 
interactions. Pharmacokinetic drug interactions occur when one drug affects the 
absorption, distribution, metabolism, or excretion of another. Pharmacodynamic drug 
interactions occur when two drugs have additive or antagonistic pharmacologic 
effects.3 
1.1 Epidemiology of drug interactions  
The probability of a drug interaction increases exponentially in hospitalised4-6 and 
ambulant patients7, 8 with the number of drugs a patient is taking. Two developments 
cause an increase of polypharmaceutical combination therapies in highly developed 
health care systems: First, an increased life expectancy which leads to an increase of 
chronic diseases and therefore leads to an enhanced demand for drugs, which is 
associated with the necessity of one individual patient to be treated by multiple 
practitioners or specialists: Second, due to chronic diseases long-term therapies and 
preventive actions become more important.9 The number of drugs taken at the same 
time is clearly higher in hospitalised patient settings5, 10-13 than in ambulatory 
patients13-16 (Figure 1). Mentioned studies (Figure 1) assume a good compliance 
which may lead to an overestimation of drug exposure.9 In general the intake of over-
the-counter (OTC) drugs for self-medication is frequent.17 In ambulatory patients the 
actual risk of drug interactions with self-medication is often not considered and might 
therefore be underestimated.  
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Figure 1: Review of drug use associated with patients age (specified above as age group / 
number of drugs (author).9 The number of drugs used per defined period of drug therapy is clearly 
higher in hospitalised patients5, 10-13 compared to ambulatory patients13-16. 
 
 
 
Egger et al.6 showed in a study at the University Hospital Basel that 53.8% of 
potential drug interactions at discharge resulted from a change of the medication 
during the hospital stay. Straubhaar et al.18 observed in a study at the University 
Hospital Basel that hospitalisation of patients with heart failure results in an increase 
in the number of drugs prescribed per patient and, thereby, also in the number of 
potentially interacting drug combinations per patient. During the hospital stay a close 
medical monitoring combined with continuous nursing and therapeutic care is 
generally guaranteed. But this may profoundly change after discharge. Therefore, 
epidemiologic post-marketing surveillance investigations in ambulatory patients are 
of particular importance for drug safety.19 
In her thesis Käser20 assessed 22 potential drug interactions of clinical relevance 
(major and moderate) and 65 of ‘possibly’ clinical relevance (major, moderate and 
minor) per 100 outpatients per year. Reported incidences in outpatients range from 
9.2% to 70.3% for drug interactions of any severity and from 1.2% to 23.3% for those 
considered of major relevance.21-27 This large ranges may be explained by 
investigations in different study populations or different definitions used for the clinical 
relevance of potential drug interactions.19  
Despite the high incidences of potential drug interactions the number of manifest 
adverse events is rather low.28-31 Studies thus far have not provided conclusive data 
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with respect to the frequency of prescribing interacting drugs and the occurrence of 
manifest adverse events caused by drug interactions in outpatients. Juurlink et al.32 
recognised the need to examine clinical outcomes of drug interactions in a 
population-based fashion. They delivered data on three drug interactions that involve 
commonly used medications and that produce specific toxic effects. Elderly patients 
taking glyburide hospitalised for hypoglykaemia were more than 6 times as likely to 
be treated with co-trimoxazole, patients admitted with digoxin toxicity about 12 times 
more likely to be treated with clarithromycin and patients treated with angiotensine-
converting enzyme inhibitors (ACEI) admitted with hyperkalaemia were about 20 
times more likely to have been treated with a potassium-sparing diuretic.  
 
In the literature, the prevalence of potential drug interactions is often expressed as 
percentage of exposed patients. This fact does not consider that one patient may be 
affected by several potential drug interactions and that the prevalence is biased by 
the number of drugs taken together.9 Alternatively, the frequency of potential drug 
interactions can be expressed by the number of potential drug interactions relating to 
the number of possible double combinations of drugs which can be calculated 
according to the equation 33.  
 
  
 
 
The frequency of clinical relevant potential drug interactions is about 6% and of 
highly relevant potential drug interactions below 2% (Figure 2).9  
Number of drug pairs  = 
n·(n-1) 
2 
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Figure 2: Reported frequencies of potential drug interactions of major and moderate5, 34-38 or 
only major7, 34-36, 38-40 clinical relevance relating to the number of possible double combinations 
of drugs.9 
 
 
 
1.2 Management of potential drug interactions 
The identification of patients at risk and an accurate management of their drug 
therapy are important challenges for health care professionals to avoid serious 
clinical consequences caused by adverse drug reactions. This process of maximizing 
the benefits and minimizing the risks of a drug therapy for individual patients is 
complex and there are many steps where errors can occur. The mission of health-
care providers is to provide systematic pharmaceutical care to reduce preventable 
drug-related morbidity and mortality.41 The Pharmaceutical Care Network Europe 
(PCNE) advanced this systematic approach.42 They classified drug-related problems 
(DRPs) according to their possible causes, possible interventions and the outcomes 
of interventions. The PCNE classification was designed to be used in research, as a 
process indicator in experimental pharmaceutical care studies and as an instrument 
to help health care professionals to document DRP-information in the pharmaceutical 
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care process (Table 1). Amongst possible negative outcomes of drug therapies drug 
interactions pose an important problem. The possible causes of DRPs lie at 
prescribers’, pharmacists’ or patients’ level and interventions to prevent adverse 
outcomes due to DRPs are installed at these levels. Any deviation from the intended 
beneficial effect of a drug therapy results in a drug-related problem.43 An optimal 
therapeutic outcome is only achieved with the absence of DRPs.41 Drug-related 
mortality and morbidity pose a major problem to health care. The rates of drug-
related hospital admissions found in two meta-analyses44, 45 were up to 5.3% and 
Winterstein et al.46 found a median preventability rate of drug-related hospital 
admissions of 59%. The newspaper headline ‘Once a $76.6 billion headache, now a 
$177.4 billion migraine’ describes the increasing economic load caused by DRPs in 
the USA between 1995 and 2000 after cost-of-illness analysis by Ernst and Grizzle47. 
There is a need to reduce economic and medical burdens caused by DRPs by their 
identification, prevention and solution in a process of pharmaceutical care48. A study 
of admissions to an Australian hospital found that drug interactions accounted for 
4.4% of DRPs encountered.49 
According to the definition of PCNE a DRP is an event or circumstance involving 
drug therapy that ‘actually’ or ‘potentially’ interferes with desired health outcomes.42 
According to this definition a drug interaction can be considered to be ‘potential’ in 
the constellation of patients’ drug therapy or ‘manifest’ when leading to an adverse 
event. Drug interactions are often predictable based on an understanding of simple 
pharmacologic properties because they are caused by the same pharmacokinetic 
and pharmacodynamic principles that determine the behaviour of drugs in the 
body.32, 50 Only few potential drug interactions do lead to ‘manifest’ outcomes and 
little information is available about the epidemiology of adverse outcomes. Most 
evidence is derived from case reports, volunteer studies, or investigations of potential 
drug interactions in hospitalised patients.32 It is very difficult for health care providers 
to predict the manifestation of a drug interaction. Hence, the statement ‘Predicting 
drug interaction outcomes – do we do better than meteorologists?’ by Hansten and 
Horn51 describes the incertitude in the process of pharmaceutical care to minimise 
risk resulting from drug interactions. 
 
A drug interaction that is likely to cause an adverse outcome in one patient may have 
no effect on another patient. Therefore, it gets more and more important to provide 
General introduction 
 19
information about patient risk factors. Bergk et al.33 revealed that 11.6% of major or 
moderate potential drug interactions are only relevant in predisposed ambulatory 
patients. The variability among patients can be explained by the influence of a 
multiplicity of factors like e.g. advanced age, co-morbidities, pharmacogenetic 
influences. For example, the increased risk of hyperkalaemia in a patient treated with 
an ACEI and a potassium-sparing diuretic who also is a diabetic with renal 
impairment is obvious. A patient who is deficient in a cytochrome P450 isoenzyme 
(CYP) may be less likely to manifest an adverse event caused by a drug interaction. 
For example, a CYP2D6 deficient patient may have an adequate therapeutic 
response with a low dose of a drug metabolised by CYP2D6 (e.g. simvastatin) 
compared with patients with normal or high CYP2D6 activity.52 When taking a potent 
CYP2D6 inhibitor (e.g. fluoxetine) there will be no interaction with simvastatin in the 
CYP2D6 deficient patient but there might be a substantial increase in serum 
simvastatin in patients with normal or high CYP2D6 activity.53 It is possible to 
determine a person’s genotype or phenotype for many of the CYP isoenzymes, but 
this is used primarily in research rather than as clinical tool for predicting drug 
response. As these procedures become more automated and less expensive, 
however, it is likely that they will become more widely used for clinical management, 
at least for selected patients.53 
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Table 1: The basic Pharmaceutical Care Network Europe Classification (PCNE) 
scheme for drug related problems 
 Code Primary domains 
Problems P1 Adverse reaction(s) 
Patient suffers from an adverse drug event 
 P2  
 
Drug Choice Problem 
Patient gets or is going to get a wrong (or no drug) drug for his/her disease 
and/or condition 
 P3 Dosing problem 
Patient gets more or less than the amount of drug he/she requires 
 P4 Drug Use/Administration Problem 
Wrong or no drug taken/administered 
 P5 Interactions 
There is a manifest or potential drug-drug or drug-food interaction 
 P6 Other 
Causes 
 
C1 Drug/Dose Selection 
The cause of the DRP can be related to the selection of the drug and/or 
dosage schedule 
 C2  
 
Drug Use Process 
The cause of the DRP can be related to the way the patient uses the drug, in 
spite of proper dosage instructions (on the label) 
 C3 Information  
The cause of the DRP can be related to a lack or misinterpretation of 
information 
 C4 Patient/Psychological 
The cause of the DRP can be related to the personality of the patient. 
 C5 (Pharmacy) Logistics 
The cause of the DRP can be related to the logistics of the prescribing or 
dispensing mechanism 
 C6 Other 
Interventions I0 No intervention 
 I2 At prescriber level 
 I2 At patient (or carer) level 
 I3 At drug level 
 I4 Other 
 
‘The Swiss cheese model’ by James Reason54, a British psychologist, has become 
the dominant paradigm for analysing medical errors and patient safety incidents. It 
was adapted by Hansten and Horn55 to the problem of drug interactions which 
systematically illustrates the avoidance/occurrence of an adverse drug reaction 
caused by a drug interaction (Figure 3). Because adverse drug reactions resulting 
from drug interactions are almost completely preventable it is important to identify the 
steps at which that prevention can take place.55 Perfect systems do not exist. The 
holes in the Swiss cheese represent gaps in the defenses (Figure 3).54  
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Figure 3: The Swiss cheese model. Adapted by Hansten and Horn55 from the ‘Swiss cheese model 
of accident causation’ by Reason56. The hazard (in this case a drug interaction) must traverse the 
layers of defense for an adverse drug event to occur. In this case, the patient’s pharmacogenetic 
makeup protects against an adverse event. The holes in the cheese represent the gaps in defenses. 
 
 
 
If managed adequately, many drug interactions do not result in clinical 
manifestations. The risk of drug interactions often can be reduced by close 
monitoring, dose adjustment and/or coordinated sequence of administration. Bergk et 
al.33 revealed that only 25.3% of potential drug interaction of major severity offered 
no management options and should thus be avoided. Anyhow, Chen et al.57 found an 
incidence of 1.9 per 1000 patient years (95% confidence interval (CI) 1.5, 2.3) of 
prescribed potentially hazardous/contraindicated drug interactions. They identified 
multiple possible causes (e.g., lack of knowledge of the drug interaction or of the 
patient medication history) and system failures (e.g., incomplete medication records, 
communication between primary and secondary care or between the prescriber and 
the patient) for the dispensing of contraindicated drug combinations.  
1.2.1 Drug interaction information sources 
In the past 40 years more than 20000 journal articles on drug interactions have been 
published. This flood of information has overwhelmed even the most dedicated and 
compulsive of health care providers.58 No one can possibly memorise all the potential 
drug interactions that have been identified to date, and new interacting drug pairs are 
identified every month. To cope with this task drug interaction compendia in the form 
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of books, computer or personal digital assistant (PDA) software or online databases 
are offered to health care providers. Studies revealing the prevalence of potential 
drug interactions often reference the US-database by Thompson Micormedex™59 or 
the British Stockley’s drug interactions60, which can be considered as standard 
referenced information sources. In Austria, Germany and Switzerland a drug 
interaction database is implemented in the drug information Pharmavista®61 which is 
adapted from the German ABDA-Database62 for the Swiss market and is used in all 
community pharmacies and also by some physicians. This database is also available 
online as a subscription-only service.  
Simply knowing that two drugs may interact does not provide enough information for 
the health care provider.53 It is also important to have information on measures that 
can be taken to reduce the likelihood of an adverse outcome. Therefore, drug 
interaction monographs have to contain information about the potential adverse 
effect, the rating of severity of the potential adverse event, the mechanism of the 
interaction, and suggestions for the clinical management including dose-adjustment, 
sequential dosing time, alternative therapies, monitoring or patient related risk 
factors. Bergk et al.63 revealed that German practitioners wish more informative 
support on drug interactions, especially concerning management. In particular, 
information about non interacting alternative therapies was thought to be lacking. 
1.2.2 Drug interaction classification systems 
It is often difficult to distinguish clinically important from unimportant drug 
interactions. It has become unrealistic to expect individual practitioners to read all of 
the relevant data and determine on their own which drug interactions are the most 
important clinically.58 Accordingly, most books and software evaluating drug 
interactions use classification systems to help the health care provider with this 
process. 
In the database Pharmavista® potential drug interactions are classified into ‘severe’ 
(life-threat / intoxication / permanent harm), ‘moderate’ (frequent therapeutic 
problems / combination can be administered but close monitoring required), ‘minor’ 
(increased or decreased drug effect / only specific subgroups affected), ‘negligible’ 
(Usually induces no or limited clinical effects / generally no modification of therapy 
required) and ‘external specifications’ (only assumed or described in particular cases 
/ clinical consequences unclear). Studies using the Pharmaceutical Specialities in 
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Sweden (FASS) classification divided major drug interactions into those that could be 
managed by dose adjustment (category C) and combinations that should be avoided 
(category D).8, 22 However, category D still includes drug combinations that can be 
therapeutically useful and safely administered under certain circumstances.33 Apart 
from dosage, there are further factors modulating the risk arising from drug 
interactions: Some are only relevant in predisposed persons; others are blunted if the 
interacting pair is combined with further co-medication (e.g., potassium substitution in 
patients receiving digoxin and a potassium-sparing diuretic), and yet others only 
occur when the combination is administered strict concurrently and can be avoided 
by temporally separated administration interval of sufficient length (e.g., aluminium or 
magnesium antacids combined with ciprofloxacin64).33  
Earlier studies reported frequencies of drug interactions and classified them 
according to their potential severity (e.g., major, moderate, minor). Bergk et al.33 used 
the classification of adverse effects by Edwards and Aronson65 (Table 2) which 
incorporates grading of the clinical relevance together with management options to 
estimate the risk arising from drug interactions. They developed an algorithm (Figure 
4) to differentiate between drug combinations that require specific management 
efforts and those that should be avoided by all means. 
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Table 2: Classification of adverse effects induced by drug interactions modified after Edwards’ 
and Aronson’s classification of adverse drug reactions65 by Bergk et al.33 
 
Type of drug interaction Characteristics Management options* Examples 
A: Augmented (dose-
related) 
Related to pharmacologic 
action of drugs 
Extent: Gradual or dose-
dependent change mostly 
indicated by a clinical 
surrogate 
Management possible 
Mechanism: 
Pharmakokinetic or 
pharmacodynamic (additive 
effect of both drug on same 
target system) 
Any or all of the following: 
Reduce dose, substitute or 
compensate by third 
compound, or change route 
of administration or separate 
cimetidine + theophylline 
acarbose + glibenclamide 
digoxin + potassium-sparing 
diuretics 
calcium + digoxin 
B: Bizarre (not dose-
related) 
Not related to 
pharmacologic action of 
drugs and any or all of the 
following: 
Extent: Nongradual or dose-
independent change, mostly 
no clinical surrogate 
indicating the extent 
Management impossible 
Mechanism: Unknown or 
pharmacodynamic with a 
nongradual or dose-
independent or sudden 
effect. 
Avoid sotalol + tricyclic 
antidepressant (QT 
prolongation) 
paroxetine + St. John’s wort 
(serotonine syndrome) 
allopurinol + captopril 
(hypertensitivity reactions) 
C: Chronic (dose- and time-
related) 
Dependent on cumulative 
dose or continuous long-tem 
use 
Avoid long-term use acetaminophen + 
carbamazepine (induced 
hepatotoxity) 
D: Delayed (time-related) Usually dose-related 
Occurs or becomes 
apparent sometime after 
use of combination 
Avoid L-Asparaginase + 
epipodophyllotoxin 
(treatment-related 
leukaemia) 
E: End of use (withdrawal) Occurs after withdrawal of 
one drug because of 
adaptive effects after long-
term exposure 
Withdraw slowly Beta-blocker + clonidine 
F: Failure (failure of 
therapy) 
Reduced pharmacologic 
action of one or both drugs  
Extent: Gradual or dose-
dependent change mostly 
indicated by a clinical 
surrogate 
Management possible 
Mechanism: 
Pharmacokinetic or 
pharmacodynamic 
Either increase dose or 
change route of 
administration or separate 
or both 
alprazolam + St. John’s wort 
carbamazepine + 
theophylline 
levothyroxine + iron 
* Different possibilities of how drug interactions can be managed; but not every option applies to all examples. 
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Figure 4: Management-oriented algorithm according to 4 decision layers for systematic 
evaluation of drug interactions by Bergk et al.33 The type of drug interaction is classified according 
to Edward and Aronson65 as exemplified in Table 2. 
 
 
 
Hansten and Horn58 used a similar management-oriented approach to innovate a 
new drug interaction classification system. They applied this classification into their 
drug interaction compendium ‘Drug Interactions: Analysis and Management’50 and 
the booklet ‘The top 100 Drug Interactions – A Guide to Patient Management’66. The 
so called ‘OpeRational ClassificAtion for drug interactions’ (ORCA) (Table 3) was 
developed by the Drug Interaction Foundation with input from an international group 
of physicians. They perceived the deficiencies of the drug interaction classification 
systems used in the United States and Europe and aimed to improve the clinical 
utility of classification systems. This classification enables health care providers to 
decide ultimately on a course of action (or inaction) for each potential drug interaction 
giving them information on management options that can reduce patient risk.58  
 
Interacting drug combination 
Contraindicated, 
major, moderate 
Minor, unspecified 
Type A, E, F 
(in principle manageable) 
Type B, C, D 
(in principle to avoid) 
Non-interacting 
alternative  
 
Therapeutically doubtful 
benefit 
Only relevant in 
predisposed patients 
Relevant in  
all patients 
Only relevant in 
predisposed patients 
Relevant in  
all patients 
Severity 
Type of drug interaction (Manageability) 
Risk-benefit assessment 
Patient-related risk 
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Table 3: Operational Classification of Drug Interactions (ORCA) innovated by Hansten and 
Horn50, 58, 66 
 
Class Definition Characterisation 
1 Avoid Combination Risk of combination outweighs benefit 
2 Usually avoid combination Use only under special circumstances 
- Interactions for which there are preferably 
alternatives for one or both drugs 
- Interactions to avoid unless the benefit is judged to 
outweigh the increased risk 
3 Minimise Risk Assess risk and take one or more of the following 
actions if needed: 
- Consider alternatives: Alternatives may be available 
that are less likely to interact 
- Circumvent: Take action to minimise the interaction 
(without avoiding combination) 
- Monitor: Early detection can minimise the risk of an 
adverse outcome. 
4 No Special Precautions Risk of adverse outcome appears small 
5 Ignore Evidence suggests that the drugs do not interact 
 
1.2.3 Computerised drug interaction screening systems 
One of the responsibilities of pharmacists is to prevent patients from unsafe or non-
effective drug regimens. In particular they should avoid the dispensing of interacting 
combinations of drugs that may cause hazardous adverse effects. In Switzerland and 
in other countries, every community pharmacy is obliged to use a computerised 
screening system for this task. Computerised drug interaction screening software 
analyses prescriptions prospectively for potential drug interactions. There is good 
evidence that electronic decision support by drug interaction surveillance software in 
the prescription fulfilment process can reduce the number of potentially hazardous 
drug interactions.38, 67-69 Halkin et al.38 revealed that drug interaction surveillance 
software in community pharmacies and physician offices can reduce the dispensing 
of prescriptions with severe interactions up to 67.5 %. Malone et al.69 reported that 
between 20% and 46% of prescription drug claims with 25 clinically important 
potential drug interactions were reversed when pharmacies were alerted. On the 
other hand, available systems have been shown to have significant deficiencies.70 
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Hazlet et al.58 showed that the performance (sensitivity, specificity, and positive and 
negative predictive value) (Table 4) of most tested drug interaction screening 
programs was suboptimal.  
 
Table 4: Factors to evaluate the performance of drug interaction screening programs adapted 
by Hazlet et al.71 
 
Factor Definition 
Sensitivity Ability of the software program to correctly identify those drug 
interaction pairs that were defined as clinically important (number 
of true positives / [number of true positives + number of false 
negatives]) 
Specificity Ability of the software to ignore drug interaction pairs that were not 
define as clinically important (number of true negatives / [number 
of true negatives + number of false positives]) 
Positive predictive value Probability that when a warning was issued by the computer, it 
was for a DDI defined as clinically important (number of true 
positives / [number of true positives + number of false positives]) 
Negative predictive value Probability that the absence of a computer alert reflected the 
determination that no clinically important drug interaction existed 
(number of true negatives / [number of true negatives + number of 
false negatives]) 
 
Barrons72 evaluated these factors for PDA software products for drug interactions 
and found a greater than 90% ability to detect important and to ignore unimportant 
interactions for 4 of 9 software products whereas 2 of them were evaluated to be 
more comprehensive and easier to use than the others. Vonbach et al.73 compared 
four drug interaction screening programs and found for Pharmavista®61 the highest 
sensitivity with an acceptable positive predictive value and specificity. Furthermore, 
they evaluated the drug interaction monographs of Pharmavista®61 positively as 
comprehensive due to very useful descriptions regarding the effect, mechanism, 
clinical management and discussion of evidence and negatively because the 
literature is not clearly referenced. German general practitioners were unsatisfied 
with the contents of drug interaction information sources. 63 In particular they missed 
information about the mechanism of a drug interaction and the management 
guidelines including the advice for dose adjustment and about alternative therapies. 
Hansten53 complains that management guidelines in the current drug interaction 
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information sources are often inadequate. He recommends inclusion of information 
on measures that can be taken to reduce the likelihood of an adverse outcome.58, 74 
1.2.3.1 Computerised drug interaction alerts 
Too many alerts complicate the medication surveillance because the identification of 
relevant signals becomes more difficult.2 Thus, knowing that most of the time the 
patient will not suffer from an adverse outcome, health care providers ignore most 
drug interaction alerts provided in ambulatory care.53 Several recent studies have 
focussed on computerised drug interaction alerts and how health care providers 
perceive them. Weingart et al.75 revealed that general practitioners overrode 89% of 
level 1 (severe) and 96% of level 2 (moderate) drug interaction alerts. Chui and 
Rupp76 and Murphy et al.77 found comparable results for community pharmacists’ 
responses to drug interaction alerts. In these studies override was defined as the 
absence of any intervention by the health care provider. Reasons given for overriding 
alerts are78: 
 
- The patient was no longer taking the interacting medication 
- The interaction was not clinically significant 
- The patient was stable on the combination 
- The benefit of the treatment outweighed the risk of the interaction 
 
In a questionnaire survey by Magnus et al.79 22% of general practitioners admitted 
that they frequently override drug interaction alerts without properly checking them. 
Abarca et al.80 examined community pharmacists’ attitudes towards computerised 
drug interaction alerts; despite a large proportion of clinically unimportant alerts, 
community pharmacy managers did not believe these alerts were meaningless or a 
waste of time. However, they were not completely confident that their computer 
systems provided them with meaningful drug interaction alerts. 
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1.2.3.2 Determinants for interventions by pharmacists because of drug 
interaction alerts 
A diploma thesis completed in our group Kurth81 analysed 277 drug interaction alerts 
in 5 Swiss community pharmacies. He revealed that 45% of the drug combinations 
with potential to interact were first time prescriptions, 26% were prescribed by 
different physicians. Furthermore, 10% of drug combinations at risk to interact 
showed less than 10 days of potential overlap. A bigger study by Buurma et al.82 
analysed 2572 drug interaction alerts in 63 Dutch community pharmacies and 
revealed that different prescribers were involved in 21% of alerts and 31% of all 
alerts occurred for the first time. Pharmacies intervened (= modification of the 
prescription, communication with the prescriber, or communication with the patient) 
after first time alerts with a 7.3-fold, for highest severe potential drug interaction with 
a 2.1-fold, and for elderly patients with a 1.7-fold higher likelihood. Prescribing by 
different prescribers was a negligible determinant. In contrast, Tamblyn et al.83 
assessed that patients who had a single primary-care physician or a single 
dispensing pharmacy were less likely to be prescribed potential drug interactions. 
Many pharmacists find that computerised drug interaction screening systems detect 
a large number of drug interactions of questionable clinical significance.53 Buurma et 
al. 82 found a high frequency of 17 drug interaction alerts per pharmacy per day. 
Kurth81 revealed in his diploma thesis that the number of drug interaction alerts per 
prescription is dependent to the software configurations of Swiss community 
pharmacies which can be configured to flag only potential drug interactions of 
moderate and/or high severity. Depending on the level of these filters he observed 2 
(level 1 = ‘severe’) to 180 (level 1 = ‘severe’, ‘moderate’ and ‘minor’) drug interaction 
alerts per pharmacy per day. 
1.2.3.3 Recommendations for improving the management of potential drug 
interactions  
Community pharmacists are a critical component in the medication use process since 
they are often the last line of defense against potentially harmful drug interactions. 
However, several gaps in the community pharmacy drug interaction screening 
processes have been identified. These include failure to properly screen for potential 
drug interactions, inadequate drug interaction surveillance software and information 
sources, and an overwhelming number of clinically irrelevant or insignificant alerts.80  
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To improve the drug interaction management by health care providers Hansten53 
makes the following recommendations: 
 
- Improve the drug interaction knowledge of health care providers 
- Improve computerised drug interaction screening systems 
- Provide information on patient risk factors that increase the chance of an 
adverse outcome 
- Incorporate pharmacogenetic information into risk assessment 
- Provide information on drug administration risk factors that increase the 
chance of an adverse outcome 
- Improve patient education on drug interaction 
 
Discussions led to optimisation of the current drug interaction management in 
community pharmacies in Switzerland and Germany. The Medicines Commission of 
Swiss Pharmacists (AKA) launched a debate to adapt the currently used drug 
interaction softwares and the classification system of the drug interaction database. 
To enrich and stimulate this debate we aimed to explore the current situation in 
community pharmacies. In particular, we projected to examine community 
pharmacists’ use of, satisfaction with and expectations towards drug interaction 
information sources and their management of drug interaction alerts provided by drug 
interaction surveillance systems. 
 
The consideration of additional risk factors and patients’ self-medication pose often a 
problem in the management of potential drug interactions. Therefore, we aimed to 
analyse the influence of risk drug and different risk factors and their combinations on 
the development of a specific adverse outcome (hyperkalaemia). Furthermore, we 
analysed drug interactions with drugs purchase for self-medication and surveyed 
patient knowledge. 
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2 Aims of the thesis 
Project A: Potential drug interactions rarely manifest adverse effects. Hyperkalaemia 
belongs to the most frequent electrolyte abnormalities in clinical practice. 
Drugs have been recognised as a primary or contributing cause of 
hyperkalaemia, especially when combined and/or administered to patients 
with underlying risk factors. The prevalence of potentially interacting drug 
combinations among potassium supplements, potassium sparing diuretics 
and ACEI or ARB is very high in ambulatory as well as in hospital settings.
The objective of this project was to analyze the influence of the known risk 
factors for hyperkalaemia on the velocity to develop hyperkalaemia in 
hospitalised patients. 
 
Project B: OTC drugs can be used for self medication without advice of a pharmacist 
or a physician. Freely available, its use is often perceived as safe by the 
customers. The lack of professional supervision may carry an increased 
risk of adverse drug effects including those caused by drug interactions.  
It was the aim of this project to asses the prevalence of potential drug 
interactions with selected prescription only medicines (POM) and OTC 
drugs in passer-by and regular customers as well as their awareness of 
these potential drug interactions. 
 
Project C: In some countries, including Switzerland, community pharmacies are 
obliged to keep a medication history of all dispensed prescription drugs 
and to check prescriptions to prevent the use of unsafe drug regimens 
including those caused by potentially interacting drugs. To comply with 
these statutory requirements, almost all pharmacies use computer 
software systems for the quality assurance of pharmacotherapy. These 
systems identify potential drug interactions, alert the pharmacy team to 
intervene before dispensing potentially interacting drugs, and serve as a 
drug interaction information source.  
The objective of this postal questionnaire survey was to analyze the 
current drug interaction management in Swiss community pharmacies 
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with a particular focus on electronic systems and to compare the results 
with those expressed by German general practitioners in a recent survey. 
 
Project D: It has been revealed that physicians and pharmacists ignore the majority 
of computerised drug interaction alerts in primary care. In project C 
pharmacists reported to consider drug interaction alerts, but they were 
overwhelmed by inappropriate alerts because of a lack of specificity of 
their drug interaction systems.  
The purpose of this study was to explore the process of identification, 
analysis and management of drug interaction alerts generated by 
community pharmacies’ computer systems.  
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3 Project A: The influence of risk factors on the velocity to 
develop hyperkalaemia 
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Abstract 
Background/objective:  
 
Drugs have been recognised as a primary or contributing cause of hyperkalaemia, 
especially when administered to patients with underlying risk factors. The objective of 
this study was to analyse the influence of the known risk factors for hyperkalaemia on 
the velocity to develop hyperkalaemia. 
 
Study design/methods:  
 
Clinical characteristics, laboratory data and medication profiles of patients developing 
hyperkalaemia (serum potassium ≥ 5.0mmol/L) hospitalised between 2000 and 2004 
in the University Hospital Basel were recorded. Factors associated with a high 
velocity to develop hyperkalaemia were detected using a multiple logistic regression 
model. Subsequently, the velocity to develop hyperkalaemia during a defined 
observation period was compared between patients with one and patients with ≥2 
risk factors. Finally, the dose effects of drugs identified as risk factors for a high 
velocity to develop hyperkalaemia were analysed using two sample comparisons. 
 
Results:  
 
A random sample of 551 hospitalised patients was analysed. Compared to the drug 
treatment at entry, during the hospitalization significantly more patients were treated 
with drugs associated with hyperkalaemia such as heparins (p<0.001), angiotensin 
converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) 
(p=0.002), potassium supplements (p<0.001), potassium-sparing diuretics (p<0.001) 
and/or NSAIDs or COX-2 selective inhibitors (p<0.001). Risk factor associated with a 
high velocity to develop hyperkalaemia were use of potassium supplements 
(adjusted odds ratio = OR 3.386, 95% CI 2.251, 5.091), severe renal impairment (OR 
3.119, 95% CI 2.007, 4.850), use of ACEI or ARB (OR 2.642, 95% CI 1.742, .4.006), 
use of potassium-sparing diuretics (OR 2.065, 95% CI 1.310, 3.254), and diabetes 
mellitus (OR 1.525, 95% CI 1.005, 2.313). The velocity to develop hyperkalaemia 
significantly increased in patients with ≥2 of such risk factors. Dose-effects could be 
Project A: Risk for a high velocity to develop hyperkalaemia 
 35
found for potassium supplements (p=0.006) and potassium sparing diuretics 
(p=0.007), but not for ACEI or ARB (p=0.289). In contrast, the use of kaliuretics (loop 
diuretics or thiazides) was associated with a decreased velocity to develop 
hyperkalaemia in patients with serious renal impairment (p=0.016) and in patients 
treated with ≥2 drug classes associated with a high velocity to develop 
hyperkalaemia (p=0.001). 
 
Conclusions:  
 
Risk factors associated with a high velocity to develop hyperkalaemia are use of 
potassium supplements > severe renal impairment > use of ACEI or ARB > use of 
potassium-sparing diuretics > diabetes mellitus. Coincidence of two or more of these 
risk factors is associated with an even faster development of hyperkalaemia. 
Clinicians should be aware of these risk factors in order to avoid a rapid development 
of potentially life-threatening hyperkalaemia. 
Project A: Risk for a high velocity to develop hyperkalaemia 
 36
Background 
Potassium disorders belong to the most frequent electrolyte abnormalities in clinical 
practice. Hyperkalaemia is less common than hypokalaemia but potentially more 
serious, especially if potassium levels are rising rapidly. [1] In hospital settings, drugs 
have been recognised as a major cause of hyperkalaemia in up to 75% patients 
presenting with this electrolyte abnormality. [2] Reported incidences of 
hyperkalaemia vary from 1.1% to 10%, depending on the threshold used for 
hyperkalaemia, which ranges from 5.0 mmol/L to 6.0 mmol/L. [2, 3]  
Several drugs have been identified as a primary or contributing cause of 
hyperkalaemia. [2, 4, 5] Especially when administered to patients with underlying 
disturbances in potassium homeostasis, hyperkalaemia induced by these drugs can 
occasionally become life-threatening. [2] Juurlink et al. recognised increasing rates of 
hyperkalaemia due to the widespread use of spironolactone after the publication of 
the Randomised Aldactone Evaluation Study (RALES). [6, 7] Use in patients with 
pre-existing risk factors for hyperkalaemia, inappropriately high doses of 
spironolactone, additional medications contributing to hyperkalaemia, inadequate 
clinical or laboratory monitoring and no clear indication for critical drugs were 
considered to be major causes for the increasing occurrence of hyperkalaemia. [8, 9] 
The reality is, however, that spironolactone is often prescribed to patients with 
additional drug and non-drug related risk factors for hyperkalaemia [9]. Most patients, 
who developed life threatening hyperkalaemia while being treated with angiotensin 
converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) and 
spironolactone, had additional risk factors including renal failure, diabetes mellitus 
and/or treatment with non-steroidal anti-inflammatory drugs (NSAID). [10, 11] 
 
Combinations of potassium-sparing diuretics, potassium supplements and ACEI or 
ARB interact with each other due to their additive pharmacodynamic effects. [12] In a 
study performed at the University Hospital of Basel, potential drug interactions 
between potassium-sparing diuretics, potassium supplements and ACEI were most 
prevalent compared with other potentially severe drug interactions in patients at 
discharge. [13] Furthermore, besides drug interactions with statins, the combination 
of ACEI and potassium-sparing diuretics was the most prevalent potentially severe 
drug interaction in ambulatory dyslipidaemic patients. [14] Additional drugs, for 
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instance NSAIDs, cyclooxygenase (COX) -2 selective inhibitors, non-selective beta-
blockers, cyclosporine, digoxin, drospirenone, heparins, lithium, pentamidine, 
succinylcholine, tacrolimus, trimethoprim and drugs administered as a potassium salt 
as well as potassium-containing salt substitutes have been reported to be associated 
with hyperkalaemia. [2, 4, 12] Furthermore, case-control studies with multivariate 
analysis revealed that diabetes mellitus, renal impairment and use of spironolactone 
or use of ACEI are independent risk factors for hyperkalaemia in hospitalised patients 
with congestive heart failure. [15, 16]  
 
Although the velocity of the increase in serum potassium levels appears to be a risk 
factor for the development of adverse effects associated with hyperkalaemia, [1] the 
risk factors associated with a high speed for the development of hyperkalaemia have 
so far not been investigated. The objective of this study was therefore to analyse the 
influence of single and multiple drug and non-drug related risk factors on the velocity 
to develop hyperkalaemia in hospitalised patients.  
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Methods 
Study design, Patients and Data Collection 
A random sample of patients developing hyperkalaemia (serum potassium levels ≥ 
5.0 mmol/L [5]) during their hospitalisation between January 2000 and March 2004 in 
four general medical wards of the University Hospital of Basel was retrospectively 
identified using electronic clinical laboratory records. The University Hospital Basel is 
a medical-surgical teaching institution covering an urban area of approximately 
300’000 inhabitants in the Northwest of Switzerland. 
 
Laboratory data, drug and non-drug related risk factors for hyperkalaemia (identified 
as described below) were assessed for a period of minimally 2 days and maximally 
10 days, beginning at the date, when the patient’s serum potassium level began to 
rise until the date when the maximal value was measured (observation period). 
Information on drugs, demographic characteristics (age, sex, size and weight), major 
diagnoses and treatments were retrieved from the patient records. Since it was 
assumed that the risk factors associated with a high velocity for hyperkalaemia were 
among the risk factors associated with hyperkalaemia itself, such risk factors were 
identified in recent publications. Non-drug related risk factors were obtained from the 
review of Evans and Greenberg [5] and drugs potentially interfering with potassium 
homeostasis were retrieved from recent reviews of Perazella [2], Palmer [4] and 
Evans and Greenberg [5]. In addition, all drugs stopped or added within two days 
prior to the observation period were also included in the analysis.  
Patients on chronic haemodialysis, surgical patients and patients with hyperkalaemia 
on hospital admission were not included in the study. The minimal increase in serum 
potassium levels had to be 0.5 mmol/L, and at least two serum potassium levels (in 
addition to the level obtained at entrance) had to be measured during one admission. 
Patients with serum potassium levels > 4.5 mmol/L at the beginning of the 
observation period were also not included in the study. Pseudohyperkalaemic 
patients were recognised based on comments of the chemical laboratory mentioning 
haemolysed samples and could therefore be excluded from the analysis. Patient’s 
creatinine clearance (CrCl) was estimated by the Cockroft-Gault formula. [17] Severe 
renal impairment was defined as CrCl < 30 mL/min. The velocity to develop 
Project A: Risk for a high velocity to develop hyperkalaemia 
 39
hyperkalaemia was calculated as the mean daily increase in serum potassium over 
the observation period in mmol/L per day, and is given as]: 
 
maximal serum potassium level − minimal serum potassium level 
 
number of days between these two measurements 
 
For the majority of patients, more than two potassium serum levels were obtained 
during the observation period. To analyse the influence of the daily dose of drugs 
associated with a higher velocity to develop hyperkalaemia, high and low daily doses 
were defined for each drug. These definitions were based on the defined daily doses 
(DDD) by the WHO Collaborating Centre for Drug Statistics Methodology. A ’high 
dose’ was defined as a daily dose > DDD. For spironolactone daily doses > 25 mg 
were considered to be a ’high dose’. [4] The study protocol was approved and 
accepted by the regional ethics committee. 
 
Statistical analysis 
Results are expressed as proportions and as medians with the corresponding 
interquartile range (IQR). Numerical variables were tested for normal distribution 
using the Kolmogorov-Smirnov test. The non-parametric Mann-Whitney-U test was 
used for unpaired two-sample comparisons. Statistical significance was defined as a 
p-value <0.05. Statistical analyses were performed using SPSS for Windows version 
13.0 (SPSS Inc., Chicago, USA). To test for a correlation between the velocity to 
develop hyperkalaemia and the extent of hyperkalaemia, patients were grouped into 
quartiles according to their velocity to develop hyperkalaemia. The mean maximal 
serum potassium levels of these groups were then compared among each other 
using analysis of variance followed by Tukey-HSD post-hoc analysis. To compare 
risk factors that changed during the observation period, McNemar’s chi-square test 
was used. For the analysis of potential risk factors for hyperkalaemia, continuous 
variables were dichotomised. Known risk factors from the literature (see above) were 
included in a multiple logistic regression model to analyze the independent 
association of these risk factors with a higher velocity to develop hyperkalaemia. The 
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median was used as cut-point to dichotomise the velocity to develop hyperkalaemia. 
Variables independently associated with a higher velocity to develop hyperkalaemia 
in this multiple logistic regression analysis were defined as ‘major risk factors’. 
Comparison of patients with no, one and multiple risk factors were performed using 
Tukey-HSD post-hoc test. 
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Results 
Patients Characteristics 
A random sample of 600 patients hospitalised in the University Hospital of Basel 
developing hyperkalaemic serum potassium levels (≥ 5.0mmol/L) between January 
2000 and January 2004 was extracted from the electronic laboratory database, 
taking into account the inclusion and exclusion criteria described above. Of them, 49 
(8.1%) had to be excluded from the analysis due to pseudohyperkalaemia. 
Demographic and clinical characteristics of the remaining study sample containing 
551 patients are summarised in Table 1. 
At the beginning of the observation period 144 (26.1%) patients were hypokalaemic 
(serum potassium < 3.5mmol/L). These patients showed a significantly higher 
median of the velocity to develop hyperkalaemia (0.42 vs. 0.35 mmol/L per day; 
p<0.001) than initially normokalaemic patients, but the median of their serum 
potassium level at the end of the observation period was not significantly different 
compared to patients being normokalaemic at the beginning of the observation 
period (5.37 vs. 5.41 mmol/L per day; p=0.405). The number of patients with severe 
renal impairment (CrCl < 30mL/min) significantly increased from 121 (22.0%) at the 
beginning to 152 (27.5%) at the end of the observation period (p=0.031). Importantly, 
the velocity to develop hyperkalaemia was positively correlated with the extent of 
hyperkalaemia (Figure 1). 
None of the 81 deaths (14.7%) was directly attributable to hyperkalaemia. However, 
patients who died reached a significantly higher median of serum potassium level at 
the end of the observation period compared with the surviving patients (5.38 vs. 5.53 
mmol/L; p=0.025). Of 30 (5.4%) patients developing severe hyperkalaemia (serum 
potassium levels > 6.5 mmol/L), 8 died. Heart failure (37%), pneumonia (13.5%) and 
myocardial infarction (11.1%) were the most frequent causes of death. 
 
Risk factors for a high velocity to develop hyperkalaemia  
Known potential non drug-related risk factors for hyperkalaemia were obtained from 
the literature and are listed in Table 2. The most prevalent risk factors in our patients 
were advanced age, diabetes mellitus and congestive heart failure. During the 
observation period, the mean drug use significantly increased from 8 (IQR 5-10) 
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before to 10 (IQR 7-12) different drugs per patient (p<0.001). Exposure to drugs 
associated with hyperkalaemia before and during hospitalization is shown in Table 3. 
As could be expected, the drugs associated with hyperkalaemia used most often in 
our patients were heparin, ACEI/ARB, potassium supplements, potassium-sparing 
diuretics and NSAIDs. For all of these drug classes, the exposure of patients 
increased during hospitalization as compared to entry. Accordingly, the number of 
patients treated with drugs potentially causing hyperkalaemia increased from 351 
(63.7%) to 508 (92.1%) (p<0.001). Of the 144 patients that were hypokalaemic 
(serum potassium < 3.5mmol/L) at the beginning of the observation period, 133 
(92.4%) were treated with potassium supplements. The number of patients with more 
than one drug potentially causing hyperkalaemia significantly increased (p<0.001) 
from 226 (40.7%) to 315 (63.2%) during the observation period. Of the 160 patients 
with a diagnosis of congestive heart failure, 138 (86.3%) were treated with an ACEI 
or an ARB, and a potassium-sparing diuretic or a potassium supplement. 
 
In the multiple logistic regression model, drug related risk factors (Table 3) and non-
drug risk factors (Table 2) for the development of hyperkalaemia were included and 
tested for their influence on the velocity to develop hyperkalaemia. Risk factors 
independently associated with a high velocity to develop hyperkalaemia are listed in 
Table 4. The identified risk factors increased the velocity to develop hyperkalaemia in 
the following order: use of potassium supplements > severe renal impairment > use 
of ACEI or ARB > use of potassium-sparing diuretics > diabetes mellitus. Figure 2 
shows that the velocity to develop hyperkalaemia increased with a rising number of 
risk factors. Pair wise comparison by Tukey-HSD post-hoc analysis showed that the 
velocity to develop hyperkalaemia is significantly higher for patients with ≥2 as 
compared to patients with one or zero risk factors (Figure 2).  
 
Dose of drugs identified as risk factors (risk drugs) 
In an additional analysis, we focussed on the daily dose of risk drugs as a risk factor 
for the velocity to develop hyperkalaemia. Patients treated with ‘high-dose’ (daily 
doses > 3000 mg potassium chloride) potassium supplements showed a significantly 
higher median of the velocity of the daily increase in serum potassium levels (n= 99) 
than patients (n=101) treated with ‘low-dose’ potassium supplements (0.48 vs. 0.40 
Project A: Risk for a high velocity to develop hyperkalaemia 
 43
mmol/L per day; p=0.006). The median of the velocity of the daily increase in serum 
potassium levels was significantly higher in patients (n=63) treated with ‘high-dose’ 
potassium-sparing diuretics (daily doses of amiloride > 10mg or spironolactone > 25 
mg) compared with those (n=74) treated with ‘low-dose’ potassium sparing diuretics 
(0.52 vs. 0.40 mmol/L per day; p=0.007). On the other hand, there was no significant 
higher median of the velocity in the daily increase of serum potassium levels between 
patients (n=129) treated with ‘high-dose’ ACEI or ARB (daily doses > DDD) vs. those 
treated with ‘low-dose’ (n=139) ACEI or ARB (0.47 vs. 0.43 mmol/L per day; 
p=0.289). Fifty-seven (53.8%) of the 106 patients treated with spironolactone were 
treated with daily doses > 25 mg. 
 
Combinations of risk drugs 
In another analysis, we focused on combinations among the drugs associated with a 
high risk to develop rapid hyperkalaemia (potassium supplements, potassium-sparing 
diuretics and ACEI or ARB). At the end of the observation period, 410 (74.4%) 
patients obtained at least one of these drugs. Of them, 138 were treated with a 
double and 28 with a triple combination. Patients with double or triple combinations 
were compared with patients with only single drug use. The median of the velocity to 
develop hyperkalaemia was significantly lower in patients treated with an ACEI or 
ARB (n=120) versus patients treated with an ACEI or ARB combined with potassium 
sparing diuretics (n=60) (0.39 vs. 0.53 mmol/L per day; p=0.002). Furthermore, a 
significantly lower median of the velocity to develop hyperkalaemia was found in 
patients treated with an ACEI or ARB versus patients treated with the combination of 
ACEI or ARB and potassium supplements (n=60) (0.39 vs. 0.52 mmol/L per day; 
p=0.002). On the other hand, in patients treated with potassium supplements or 
potassium-sparing diuretics, the median of the velocity to develop hyperkalaemia 
was not lower than in patients treated with potassium supplements or potassium-
sparing diuretics combined with an ACEI or ARB. The velocity to develop 
hyperkalaemia in patients with triple combinations (potassium supplements, ACEI or 
ARB and potassium-sparing diuretics, n=28) equaled 0.50 (IQR 0.37-0.94) mmol/L 
This velocity is significantly higher (p<0.05) compared to patients using only one of 
these drug classes, but not significantly different as compared to patients with double 
combinations. 
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Kaliuretics 
At the end of the observation period, significantly (p<0.001) more patients were 
treated with a kaliuretic (thiazide or loop diuretic) than before the observation period 
(288 or 52.3% vs. 178 or 32.1% of the patients). Patients with severe renal 
impairment (CrCl≤ 30 mL/min) treated with kaliuretics (n=85) showed a significantly 
lower) velocity of the increase in serum potassium than patients with severe renal 
impairment without kaliuretics (n=67) (0.44 vs. 0.52 mmol/L per day; p=0.016). Out of 
167 patients treated with at least 2 of the 3 drug classes identified as risk drugs 
associated with a higher velocity to develop hyperkalaemia, 138 (82.6%) were 
treated with a kaliuretic. These 138 patients showed a significantly lower median of 
the velocity to develop hyperkalaemia compared with the remaining 29 patients of 
this group without kaliuretics (0.45 vs. 0.63 mmol/L per day; p= 0.001). 
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Discussion 
Hyperkalaemia is a life-threatening electrolyte disturbance associated with different 
drug or non-drug related risk factors. The current study reveals that several risk 
factors can contribute to a fast development of hyperkalaemia. By multivariate 
analysis, the risk factors significantly associated with a high velocity to develop 
hyperkalaemia were identified in the order: use of potassium supplements > severe 
renal impairment > use of potassium-sparing diuretics > use of ACEI or ARB > 
diabetes mellitus (Table 4). Importantly, the velocity to develop hyperkalaemia 
correlated with the extent of hyperkalaemia that was reached and was higher in the 
presence of more than one of these risk factors. 
 
Except for the use of potassium supplements, the order of the risk factors (as 
expressed by the adjusted odds ratios) is comparable with the corresponding odds 
ratios for the development of hyperkalaemia identified in a recent case-control study 
in hospitalised patients with congestive heart failure. [15] In our study, potassium 
supplements contribute most strongly to the velocity to develop hyperkalaemia in the 
multivariate model. This may be explained by the facts that in our study 144 (26.4%) 
of the patients were hypokalaemic at the beginning of the observation period and that 
most of these patients were treated quite aggressively with potassium supplements. 
These patients showed a significantly (p=0.001) higher velocity of the daily increase 
of serum potassium levels. However, in a study of 4921 outpatients treated with 
potassium supplements, only 3.6% developed hyperkalaemia. [2, 18] In comparison, 
hospitalised patients treated with potassium supplements appear to have a higher 
risk for hyperkalaemia, since hyperkalaemia was found in 15% to 40% of these 
patients. [2] This difference in the frequency of hyperkalaemia between hospitalised 
and ambulant patients treated with potassium supplements may be explained by a 
more aggressive potassium supplementation and by a higher prevalence of other risk 
factors for hyperkalaemia in hospitalised patients. 
In our study, the majority (142 or 71%) of the 200 patients treated with potassium 
supplements had an additional ‘major risk factor’ for hyperkalaemia such as severe 
renal impairment, use of potassium-sparing diuretics, use of ACEI or ARB and/or 
diabetes mellitus. 
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Several studies about hyperkalaemia highlight the risk of the potential drug 
interaction between spironolactone and ACEI or ARB. [10, 19] Palmer recommends 
that the dose of spironolactone should not exceed 25 mg per day when used in 
combination with an ACEI or ARB. [4] In agreement with this recommendation, the 
use of high-dose potassium-sparing diuretics (daily doses of spironolactone > 25mg 
or of amiloride > 10mg) significantly accelerated the velocity to develop 
hyperkalaemia in our study, whereas no such effect was observed for high-dose 
ACEI or ARB. Our study therefore supports the statements of Palmer et al. that the 
dose of spironolactone should not exceed 25mg day when used in patients with heart 
failure, in particular in patients with other risk factors for hyperkalaemia such as 
treatment with ACEI, ARB or potassium supplements and in patients with renal 
failure. [4] In our study, 20.5 % of the patients (n=60) treated with an ACEI or ARB in 
combination with potassium-sparing diuretics had severe renal impairment at the 
beginning of the observation period and of the 106 patients treated with 
spironolactone, 57 (53.8%) were treated with daily doses > 25mg. In this context, it is 
important to realise that in the RALES study spironolactone was investigated in a 
daily dose of 25mg and not at higher doses. [4] 
Although not identified as risk factors for a fast development of hyperkalaemia in this 
study, drugs associated with hyperkalaemia including NSAIDs (Table 3) could 
contribute to the development of hyperkalaemia, especially when combined with 
Although not identified as risk factors for a fast development of hyperkalaemia in this 
study, drugs associated with hyperkalaemia including NSAIDs (Table 3) could 
contribute to the development of hyperkalaemia, especially when combined with 
Kaliuretics (loop diuretics or thiazides) are effective in reducing the risk for 
hyperkalaemia. Patients at risk for hyperkalaemia could therefore be treated with 
kaliuretics. In our study, the potassium-lowering effect of kaliuretics could be 
confirmed in patients with severe renal impairment and in patients treated with ACEI, 
ARB, potassium-sparing diuretics and/or potassium supplements. The velocity to 
develop hyperkalaemia in these patients was significantly lower, if they were treated 
also with kaliuretics. However, the risk of hyponatraemia should be taken into 
consideration and the patients should be monitored closely when loop diuretics or 
thiazides are prescribed. [20] 
 
Project A: Risk for a high velocity to develop hyperkalaemia 
 47
The strength of this study is the analysis of the velocity to develop hyperkalaemia. 
Therefore we used an observational study design without a control group. This is 
different to the other studies in this field, which assessed only the occurrence of 
hyperkalaemia with the objective to identify risk factors for hyperkalaemia [15, 16]. 
Our study reveals that the velocity to develop hyperkalaemia is influenced almost by 
the same risk factors as the occurrence of hyperkalaemia. The only exception is the 
treatment with potassium supplements, which is a more pronounced risk factor for 
the velocity to develop hyperkalaemia than for the occurrence of hyperkalaemia. The 
exposure to ≥2 risk factors further enhances the velocity to develop hyperkalaemia. 
Since the velocity to develop hyperkalaemia is correlated with the extent of 
hyperkalaemia, patients with ≥2 risk factors should be monitored very closely for the 
development of potentially life-threatening hyperkalaemia. 
 
Some limitations of this study merit discussion. First, the study sample was recruited 
on four general wards in one university hospital, representing patients of one single 
community with long hospitalisation stay (18 days). The findings may therefore not be 
generalised and be transferred to other hospital or ambulatory settings. Second, the 
Cockroft-Gault formula [17] may overestimate the CrCl. A comparison with other 
methods estimating the CrCl reveals, however, that the differences are small, 
suggesting that other methods would not change our findings. [21] Third, the study 
was retrospective and the way we calculated the velocity to develop hyperkalaemia 
did assume a linear rise of serum potassium. We did not judge the linearity of the 
increase, even in patients where multiple serum potassium determinations were 
available in the observation period. Fourth, hospitalised patients are closely 
monitored and hyperkalaemia is normally quickly detected and can therefore be 
treated immediately. Similar to previous in-hospital studies, [16] only a small number 
of patients (5.4%) developed severe hyperkalaemia (serum potassium levels > 
6.5mmol/L) and more than half of the subjects developed only mild hyperkalaemia 
(serum potassium levels < 5.5mmol/L). The situation for outpatients might be 
different. In these patients, less intense monitoring may result in an increased risk of 
hyperkalaemia, which can be fatal. [22] 
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The relatively high mortality (14.7%) of patients in this study is comparable to other 
in-hospital studies. [16] This may be explained by the polymorbidity (7.diagnoses per 
patient) of the patients studied and their advanced age (72.2 years). None of the 
deaths could directly be attributed to hyperkalaemia. Nevertheless, patients who died 
showed a significantly higher maximal serum potassium level as compared to the 
entire study population, and cardiac diseases were the most frequently reported 
cause of death. 
 
Conclusions 
Risk factors associated with a high velocity to develop hyperkalaemia are use of 
potassium supplements > severe renal impairment > use of ACEI or ARB > use of 
potassium-sparing diuretics > diabetes mellitus. Coincidence of two or more of these 
risk factors is associated with an even faster development of hyperkalaemia. Since 
the velocity to develop hyperkalaemia is correlated with the extent of hyperkalaemia, 
the serum potassium levels in patients with ≥2 risk factors should be monitored 
closely to avoid life-threatening hyperkalaemia. A rapid increase in serum potassium 
(>0.5mmol/L per day) should alert clinicians to identify and possibly remove risk 
factors for hyperkalaemia. 
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Tables 
Table 1: Demographic and clinical characteristics of the patients (n=551) 
 
Characteristic  
Age in years, [median (IQR)] 72.2 (63.5-80.3) 
Sex (male) [no. (%)] 270 (49) 
Length of hospital stay in days [median (IQR)] 18 (11-30) 
Observation period in days [median (IQR)] 5 (3-6) 
Number of diagnoses for each patient [median (IQR)] 7 (6-9) 
Number of drugs [median (IQR)] 10 (7-12) 
New drugs added 2 days before or during observation period 
[median (IQR)] 
3 (2-5) 
Drugs stopped 2 days before or during observation period 
[median (IQR)] 
2. (0-3) 
Maximal serum potassium level in mmol/L [median (IQR)],  5.4 (5.1-5.8)  
Serum potassium level at the beginning of the observation 
period in mmol/L [median (IQR)], 
3.8 (3.4-4.1) 
Daily increase in serum potassium in mmol/L [median (IQR)], 0.38 (0.26-0.57) 
Creatinine clearancea in mL/min [median (IQR)], 43.3 (28.9-63.6) 
Creatinine clearancea at the beginning of the observation 
period in mL/min [median (IQR)], 
46.9 (31.9-67.9) 
IQR = interquartile range 
a Creatinine Clearance estimated by the Cockroft and Gault formula [17]. 
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Table 2: Prevalence of non-drug related risk factors for hyperkalaemia 
 
Non-drug related risk factora no. (%)  
Advanced age (≥ 65 years) 388 (70.4) 
Diabetes mellitus 166 (30.1) 
Congestive heart failure 160 (29.0) 
Severe renal impairmentb 
  Chronic kidney disease 
  Acute kidney failure 
152 (27.5) 
31 (5.6) 
36 (6.5) 
Blood transfusions 41 (7.4) 
Tubulointerstitial nephritis 14 (2.5) 
Renal sclerosis 5 (0.9) 
Obstructive uropathy 4 (0.7) 
Volume depletion 3 (0.5) 
Primary adrenal insufficiency  2 (0.4) 
Metabolic Acidosis 2 (0.4) 
Haemolysis 1 (0.2) 
Hyperglycaemia 1 (0.2) 
Acute tumor lysis, amyloidosis, amyloidosis, congenital adrenal hyperplasia, 
fluoride poisoning, gastrointestinal bleeding, Gordon syndrome, hyperkalaemic 
periodic paralysis, hyporeninaemic hypoaldosteronism (type IV Renal tubular 
acidosis), papillary necrosis, post kidney transplantation, primary hyporeninism, 
rhabdomyolysis, systemic lupus erythematosus, sickle cell disease, surgery, 
tissue trauma 
0 
Catabolic states, geophagia, vigorous exercise Data not available 
a Risk factors to develop hyperkalaemia according to Palmer [4], Evans and Greenberg [5 ]. 
b Creatinine Clearance (< 30 mL/min) estimated by the Cockroft and Gault formula [17].  
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Table 3: The study populations (n = 551) exposure to drugs associated with risk for 
hyperkalaemia before during and at the end of the observation period  
 
McNemar’s Chi-square test was performed to compare exposure to risk drugs for hyperkalaemia 
before and at the end of observation period.  
 
Drug exposure Before observation 
period, no. (%) 
At the end of 
observation period, 
no. (%) 
P-value 
Heparin 174 (31.6) 320 (58.1) <0.001 
ACEI/ARB 217 (39.4) 268 (48.6) 0.002 
Potassium supplement  139 (25.2) 200 (36.3) <0.001 
Potassium-sparing diuretic : 
Spironolactone 
Amiloride 
80 (14.5) 137 (24.9) 
106 (19.2) 
31 (5.6) 
<0.001 
NSAID/COX-2 selective inhibitor 32 (5.8) 76 (13.8) <0.001 
Digoxin 38 (6.9) 44 (8.0) 0.491 
Trimethoprim 14 (2.5) 25 (4.5) 0.073 
Calcineurin-antagonist:  
Ciclosporine  
Tacrolimus 
15 (2.7) 16 (2.9) 
13 (2.4) 
3 (0.5) 
0.855 
Antineoplastic drugs 3 (0.5) 12 (2.2) 0.019 
Nonselective beta-blocker 5 (0.9) 8 (1.5) 0.403 
Intravenous amino acids (arginine, 
lysine, epsilon-aminocaproic acid) 
4 (0.7) 4 (0.7) 1.000 
Lithium 2 (0.4) 2 (0.4) 1.000 
Drospirenone, mannitol, 
metyrapone, penicillin G 
potassium, pentamidine, post 
kidney transplantation, 
somastatin, succinylcholine 
0 0 - 
Herbal medications, high 
potassium containing food 
data not available 
ACEI = Angiotensin converting enzyme inhibitor; ARB = Angiotensin receptor blocker; NSAID = non-
steroidal anti-inflammatory drug; COX-2 = Cyclooxygenase type 2 
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Table 4: Independent risk factors significantly associated with a high velocity to develop 
hyperkalaemia  
 
In a multiple logistic regression analysis, all drugs associated with hyperkalaemia (Table 3) and non-
drug related risk factors for hyperkalaemia (Table 2) were included to identify independent risk factors 
significantly associated with a high velocity to develop hyperkalaemia.  
 
Major risk factor B OR 95% CI P-value 
Use of Potassium supplements 1.220 3.386 2.251-5.091 <0.001 
Severe renal impairmenta 1.138 3.119 2.007-4.850 <0.001 
Use of ACEI or ARB 0.971 2.642 1.742-4.006 <0.001 
Use of Potassium-sparing diuretics 0.725 2.065 1.310-3.254 0.002 
Diabetes mellitus  0.442 1.525 1.005-2.313 0.047 
a Creatinine Clearance (< 30 mL/min) estimated by the Cockroft and Gault formula [17]. 
B = Regression coefficient; OR = adjusted odds ratio; 95% CI= 95% confidence interval; ACEI = Angiotensin 
converting enzyme inhibitor; ARB = Angiotensin receptor blocker 
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Figure 1: Correlation of the velocity to develop hyperkalaemia (mean daily increase in serum 
potassium) with the extent of hyperkalaemia.  
 
Patients were grouped into quartiles regarding their velocity to develop hyperkalaemia. A high velocity 
to develop hyperkalaemia was associated with high maximal serum potassium levels (analysis of 
variance followed by Tukey-HSD posthoc analysis). 
 
Boxes represent interquartile range (25%-75%) with mean ( ) and median ( ); whisker = standard 
deviation 
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Figure 2: The velocity to develop hyperkalaemia (mean daily increase in serum potassium) 
according to the number of risk factors.  
 
The risk factors included for the calculation were severe renal impairment, diabetes mellitus and 
treatment with potassium-sparing diuretics, angiotensin converting enzyme inhibitors angiotensin 
receptor blockers or potassium supplements. The velocity to develop hyperkalaemia is higher with an 
increasing number of these risk factors. In comparison to patients without such risk factors, patients 
with one or more risk factor show a significantly higher velocity to develop hyperkalaemia (p>0.05) 
(analysis of variance followed by Tukey-HSD post-hoc analysis).  
 
Boxes represent interquartile range (25%-75%) with mean ( ) and median ( ); whisker = standard 
deviation 
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Summary 
Background and Objective 
In community pharmacies potential drug interactions between prescription only 
medicines (POM) and OTC drugs purchased for self-medication arise mainly in two 
situations: (A) if an OTC drug is purchased by a passer-by customer whose 
prescribed drug therapy is not known, or (B) if a POM or an OTC drug is requested 
by a regular customer whose prescribed drug therapy is usually recorded. With this 
study we aimed to assess the prevalence of potential drug interactions with selected 
POM and OTC drugs in passer-by and regular customers as well as their awareness 
of these potential drug interactions. 
 
Methods 
Data were collected in 14 community pharmacies in the region of Basel, Switzerland 
by observation of customer contacts and interviews with passer-by customers 
purchasing selected OTC drugs, and telephone-interviews with regular customers 
treated with selected POMs identified in community pharmacies’ databases. The 
selected POMs and OTC drugs are drugs which could lead to clinically relevant drug 
interactions of varying severity but manageable through different interventions such 
as adjustment of dose and its timing and/or monitoring of the therapy, and avoidance 
of the combination by choosing an alternative treatment. 
 
Results 
Of 1183 passer-by customers observed, 164 (14.4%) purchased at least one of the 
selected OTC drugs. 102 (62.2%) of those subjects were interviewed. 43 (42.2%) 
mentioned taking prescribed drugs, and 3 of them were exposed to potential drug 
interactions of moderate severity.  
Out of 592 regular customers selected from the community pharmacy database, 434 
(73.3%) could be interviewed.  69 (15.9%) of them were exposed to a potential drug 
interaction between purchased OTC drug for self-medication and their POM. 
Furthermore, 116 (26.7%) regular customers were exposed to potential drug 
interactions within their prescribed drugs and in 28 (6.5%) multiple (≥ 2) potential 
drug interactions were found.  
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203 (46.8%) regular customers were aware of potential drug interactions between 
their POM and OTC drugs. 96 (47.3%) of them were informed by their prescribing 
physician and 52 (25.6%) by their community pharmacist. Awareness of potential 
drug interaction was higher in younger customers [odds ratio (OR) 0.95; 95% 
confidence intervals (CI) 0.93, 0.97, p<0.0001] and higher for drug interactions 
classified as ‘severe’ [OR 1.79; 95% CI 1.16, 2.77, P = 0.009].  
 
Conclusion  
Efforts to increase awareness of potential drug interactions are needed. Although 
community pharmacies are adequately equipped with computerised drug interaction 
surveillance systems this is often not applied to self-medication. Vigilance for 
potential interactions of all drugs, including those sold over the counter, should be 
increased.  
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Background 
Over-the-counter (OTC) drugs can be used for self-medication without advice of a 
pharmacist or a physician. Freely available, their use is often perceived as safe by 
customers [1]. The lack of professional supervision may increase the risk of adverse 
drug effects including those caused by drug interactions. Availability and use of OTC 
drugs vary among different countries [2-6]. In Switzerland OTC drugs are classified 
as ‘pharmacist only’ (e.g. Levonorgestrel), ‘pharmacy only’ (e.g. Ranitidine), ‘drug 
store only’ (e.g. Paracetamol) or freely available (e.g. low-dose vitamins and 
minerals). In 2004 OTC drugs amounted to 41.9% of accredited drugs. In ambulatory 
care 72.1% of OTC dugs are sold by community pharmacies [7], 34.1% of customers 
visit Swiss community pharmacies to purchase an OTC drug [8]. 
In recent years, health authorities have encouraged self-care for minor ailments to 
reduce the cost of medical care [9]. Advertisement for OTC drugs is allowed in all 
media including television and their availability and use have increased. More and 
more drugs are switched from prescription only to non-prescription status 84. Even 
drugs such as statins and triptans, with a considerable risk of interaction have been 
switched. OTC drugs interacting with POMs like non steroidal anti-inflammatory 
drugs (NSAIDs), pseudoephedrine and dextromethorphan are commonly used by 
ambulatory patients [10]. Certain segments of the population like the elderly, children, 
organ transplant or HIV infected patients are at elevated risk of adverse drug effects 
from significant drug interactions between prescribed and OTC drugs [11, 12]. 
Some pharmacokinetic drug interactions like those between antacids and  
tetracyclines or quinolones can be managed by adjusting dose regimens or spacing 
dosing times. Other potential interactions such as that between monoamino oxidase 
(MAO) inhibitors and dextromethorphan or indirect acting sympathomimetics present 
in cough or cold medications are best avoided by choosing an alternative treatment 
[13].  
 
The first step before any intervention by a pharmacist is the identification of the 
potential drug interaction. In Switzerland community pharmacies electronically record 
all prescribed drugs for mandatory health insurance claims and this recording is 
automatically computer-checked for potential drug interactions. So far, self-
medication drugs are checked less systematically. They are often not recorded in the 
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individual medication history. The need to treat OTC drugs like all other medications 
and to monitor patients’ self-medication is more and more recognised [11]. Some 
Swiss community pharmacies have started to collect data of their regular customers’ 
self-medication using a record card.  
 
Recent studies of potential drug interactions in ambulatory care have focused only on 
prescribed drugs [14]. Little is known about the prevalence of potential drug 
interactions between prescription only and OTC drugs. In a Finnish national health 
care study clinically relevant potential drug interaction were identified among 68 (4%) 
of OTC drug users, but only 10 were at constant risk of clinically relevant drug 
interactions from continuous OTC drug use [3].  
 
In community pharmacies potential drug interactions between POM and OTC drugs 
for self-medication arise mainly in two situations (A) if an OTC drug is purchased by a 
passer-by customer whose prescribed drug therapy is not known or (B) if a POM or 
an OTC drug is requested by a regular customer whose prescribed drug therapy is 
usually recorded. Our study addresses both of these situations. We aimed to assess 
the prevalence of potential drug interaction with selected POMs and OTC drugs in 
passer-by and regular customers as well as their awareness of these potential drug 
interactions. 
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Methods 
POMs and OTC drugs were selected for their potential to cause clinically relevant 
drug interactions (Table 1). An important consideration was the possibility to handle 
the potential interactions by dose regimen adjustment, spacing dosing times, 
alternative choice of therapy, or closer monitoring (Table 1). All drug interactions had 
to be contained in the database Pharmavista® [15] which is implemented in the drug 
interaction surveillance softwares of all Swiss community pharmacies. Pharmavista® 
[15] is adapted from the German ABDA-Datenbank [16] for the Swiss market. In this 
database drug interactions are classified into ‘severe’ (the interaction can be life-
threatening for the patient or intoxications or permanent harms for the patient can 
occur), ‘moderate’ (the interaction often induces therapeutic problems, but if the 
patient is closely monitored the combination can be administered), ‘minor’ (the 
interaction can lead to increased or decreased drug effects or only specific person 
subgroups are considered’), ‘negligible’ (the interaction mostly induces no or limited 
clinical effects and generally no alterations in therapy are required) and ‘external 
specifications’ (the interaction is only assumed or described in particular cases and 
its clinical consequences are unclear). 
Passer-by customers purchasing selected OTC drugs were observed in community 
pharmacy and interviewed for their prescribed medicines. Regular customers with 
selected POMs were selected from the community pharmacies database and 
interviewed over the phone for their self-medication, their awareness of potential drug 
interaction and their source of information. 
 
Data collection 
Data were collected over a 4-week period in April 2005 in 14 out of 99 community 
pharmacies randomly selected in the region of Basel, an urban area of approximately 
450,000 inhabitants in the Northwest of Switzerland. Pharmacy patrons signed a 
letter of informed consent and all included pharmacy customers gave their consent to 
be interviewed. The study protocol was approved and accepted by the regional ethics 
committee.  
A pharmacist trained as observant researcher spent one regular working-day in each 
study pharmacy. He observed contacts with passer-by customers at the counter and 
he approached those who purchased one of the selected OTC-drugs for an interview. 
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He asked for their age and any prescribed drugs. Customers younger than 18 years 
were excluded from the study. Of customers refusing the interview, their gender and 
their reason of refusal were assessed and their age group was estimated.  
In the database of the study pharmacies the observant researcher identified regular 
customers with at least one of selected POMs (Table 1) in their medication history of 
the last 100 days. The first 12 regular customers treated with the selected POM of 
each pharmacy’s database, aged between 18 and 75 years, were included and 
demographic characteristics and medication profiles were recorded. Telephone 
interviews were performed by a structured questionnaire by one trained pharmacist. 
Interview questions referred to the awareness of potential drug interactions of the 
prescribed drug with OTC drugs and actual OTC use including frequency and dose 
(Table 2). If a potential drug interaction was detected, questions about awareness, 
management as well as adverse events were asked. At the end of the interview the 
regular customer was informed about possible potential drug interactions of its POM 
with OTC drugs. For customers that could not be interviewed demographic data, 
prescribed drugs and the reason of refusal or non-respondence were assessed.  
 
Statistical analysis 
Results are expressed as proportions and as means ± standard deviations (SD) or 
medians with the corresponding range. Independent two-sample comparison of 
single continuous variables was performed using Students’ t-test. Chi-square 
statistics were used for categorical comparisons. To analyse the association of 
covariates with regular customers’ awareness of potential drug interactions with self-
medication drugs, logistic regression analysis was performed. Covariates in a 
simultaneous model were gender, age as a continuous variable, number of 
prescribed drugs as a continuous variable, the collection of self-medication data by 
community pharmacies, the occurrence of potential drug interactions between the 
POM and other prescribed drugs, the occurrence of potential drug interactions 
between the POM and an OTC drug purchased for self-medication and treatment 
with POMs that can lead to potentially ‘severe’ drug interactions with OTC-drugs 
(Table 1). Odds ratios (OR) are presented with 95% confidence intervals (CI). 
Statistical significance was defined as p-value <0.05. Statistical analysis was 
performed using SPSS for Windows version 13.0 (SPSS, Inc., Chicago, IL 60606). 
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Results 
Observation of passer-by customers  
In 14 community pharmacies, 1183 passer-by customers were observed during 112 
hours. 164 (14.4 %) requested at least one of the selected potentially interacting 
OTC drugs (Table 1) and 102 (Age 55.2 ± 16.2 years, 62.7% female) were 
interviewed. Reasons for refusal of the interview were purchase of an OTC drug for 
another person (n=25), refusal due to lack of time or interest (n=21), poor knowledge 
of drugs prescribed (n=14) and escape (n=2). Of the interviewed regular customers, 
43 (42.2%) mentioned being on 2.2 ± 1.3 prescribed drugs. For 3 customers one of 
the selected potential drug interactions (Table 1) was found: Two potential drug 
interactions between ibuprofen and low-dose ASA and one potential drug interaction 
between ibuprofen and spironolactone.  
 
Telephone interviews with regular customers 
Of the 592 regular customers selected from the community pharmacy database 434 
(73.3%) agreed to be interviewed (Age 69.9 ± 13.1 years, 56.4% female, meanly 5.0 
± 2.1 prescribed drugs). Responders were significantly older (P < 0.001), more 
frequently female (P < 0.001) and more frequently treated with prescribed drugs than 
non-responders (P < 0.001). Main reasons for non-response (n=158) were no contact 
due to absence (44.9%) or no known telephone number (39.2%) and refusal of the 
interview due to lack of time or interest (10.8%).  
Of the 14 community pharmacies included in this study 8 (57.8%) had partial records 
of the self-medication of their regular customers and this allowed detection of some 
potential drug interactions with OTC drugs. No differences in prevalence of potential 
drug interactions between purchased OTC drugs and POMs (chi-square, P = 0.524) 
and in prevalence of drug interactions between the selected POMs and other 
prescribed drugs (P = 0.329) were found between regular customers of the two types 
of pharmacies. 
 
Prevalence of selected potential drug interactions in regular customers 
In 69 (15.9%) regular customers potential drug interactions between OTC drugs 
purchased for self-medication and POMs were found (Figure 1). In 116 (26.7%) 
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regular customers additional potential drug interactions between other prescribed 
drugs and in 28 (6.5%) multiple (≥2) potential drug interactions were found (Figure 1).  
 
MAO-inhibitors 
Of 29 customers treated with a MAO-inhibitor 17 (58.6%) could be interviewed and in 
4 of them a potential drug interactions with purchased OTC drugs were found. All 
were treated with moclobemide and purchased cold and cough medications 
containing a combination of paracetamol and the potentially interacting agents 
pseudoephedrine, phenylephrine or dextromethorphan. However, all customers 
indicated taking these drugs less than 2 to 3 times per week. None of these potential 
drug interactions were identified by their physician or pharmacist. Two of these 
customers reported warmth and dizziness after taking the cold and cough 
medications. Two customers were treated with the POM tramadol, one with the POM 
mirtazapine and one with prescribed dextromethorphan. Overall in 6 (35.3%) out of 
17 interviewed customers potential drug interactions were found. 
 
Immunosuppressants 
Out of 35 regular customers treated with immunosuppressants (cyclosporine or 
tacrolimus) 23 (65.7%) could be interviewed. One of them purchased a St. John’s 
wort preparation and 2 customers consumed grapefruit juice. None of these potential 
drug interactions were identified by their physician or pharmacist and no closer 
monitoring of immunosuppressants serum levels was carried out. None of these 
customers reported abnormal drug concentrations, toxic effect or allergic reactions. 
We found 3 other customers that were treated with prescribed St. John’s wort 
preparations. Overall in 6 (26.1%) out of 23 interviewed customers, potential drug 
interactions were found. 
 
Oral anticoagulants 
Out of 168 regular customers treated with oral anticoagulants, 134 (79.8%) were 
interviewed. 8 of them purchased NSAIDs or high-dose ASA (single dose ≥ 500mg) 
for self-medication. Five customers purchasing NSAID (diclofenac, ibuprofen or 
naproxen) reported having informed the physician and took precautions such as 
closer monitoring and dose-adjustment. All of them reported taking NSAID 2 to 3 
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times per week or less. The three customers purchasing ASA were not aware of the 
potential drug interaction and no precautions were taken. All of them reported taking 
ASA, 2 to 3 times per week or less and additionally they were treated with further 
prescribed NSAIDs (diclofenac or ibuprofen). None of the 8 customers reported a 
change in hypoprothrombinemic response or even bleedings. Furthermore, we found 
other 54 customers with potential drug interactions with prescribed ASA (single dose 
≥ 500 mg), diclofenac or ibuprofen. Overall in 62 (46.3%) out of 134 interviewed 
customers potential drug interactions were found. 
 
Potassium-sparing diuretics 
Of 81 regular customers treated with potassium-sparing diuretics 61 (75.3%) were 
interviewed and in 11 of them potential drug interactions between spironolactone and 
OTC drugs were found. Nine of them purchased NSAIDs (ibuprofen or diclofenac) 
and 2 of them potassium supplements. One customer using an OTC-NSAID was 
additionally treated with an angiotensine converting enzyme (ACE) inhibitor. This 
customer took a daily dose of 25mg spironolactone and mentioned that his serum 
potassium level is regularly monitored. Four customers that purchased OTC-NSAIDs 
were additionally treated with diclofenac in a POM dose. In 6 of 9 customers that 
purchased OTC-NSAIDs the potential drug interaction was recognised by their 
physician. Of the 2 customers that purchased potassium supplements one customer 
was additionally treated with prescribed diclofenac. All of them reported taking the 
NSAIDs for self-medication 2 to 3 times per week or more seldom. Regular 
customers that purchased potassium supplements reported that the potential drug 
interaction was recognised by a physician and that their serum potassium levels are 
regularly monitored. Both were treated with the combination because of 
hypokalaemia. No customer reported a hyperkalaemic serum potassium level, an 
adverse event due to hyperkalaemia or renal impairment. Furthermore, we found 
other 26 customers with potential drug interactions with other prescribed drugs. They 
were treated with ACE inhibitors, angiotensin receptor blockers and potassium 
supplements. Overall in 38 (62.3%) out of 61 interviewed customers potential drug 
interactions were found. 
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Tetracyclines 
Out of 132 regular customers treated with tetracyclines (doxycycline or minocycline) 
82 (62.1%) could be interviewed and 41 of them reported consumption of products 
containing polyvalent cations during their antibiotic therapy. Of them 4 took antacids 
containing magnesium and aluminium, 8 multiminerals, 4 magnesium supplements, 4 
calcium supplements and one customer an iron supplement. Furthermore, 13 
customers mentioned to take calcium containing food (milk or dairy products) at the 
same time than tetracyclines. To avoid the potential drug interactions 8 of 41 
customers ingested products containing polyvalent cations 2 to 3 hours before or 
after taking tetracyclines. Out of 36 customers with potential drug interactions a total 
of 19 mentioned to take products containing polyvalent cations daily. One customer 
reported of a therapy failure potentially caused by an interaction with calcium 
containing food. None of these potential drug interactions was recognised by their 
pharmacist or physician. Furthermore, 8 patients were treated with other prescribed 
supplements containing calcium, iron or magnesium. Overall in 40 (48.8%) out of 82 
interviewed customers potential drug interactions were found. 
 
Low-dose ASA 
Of 147 regular customers treated with low-dose ASA (≤ 300mg) 117 (79.6%) could 
be interviewed. Of them 7 purchased OTC ibuprofen. None of the potential drug 
interactions were recognised by their physician or pharmacist. All customers 
mentioned to take ibuprofen in single doses of 200mg to 600mg. None of them 
purchasing OTC drugs took daily doses of ibuprofen > 1200mg. All of them reported 
taking ibuprofen 2 to 3 times per week or less. None of them considered to take 
ibuprofen 2 hours after low-dose ASA to minimise risk. No customer reported of an 
adverse cardiovascular event. Furthermore, we found 8 other customers that were 
treated with prescribed POM ibuprofen in single doses of 400 to 600 mg. Overall in 
15 (12.8%) out of 117 interviewed customers potential drug interactions were found. 
 
Awareness of potential drug interactions in regular customers 
Of the interviewed regular customers 203 (46.8%) were aware about potential drug 
interactions between their POM and OTC drugs for self-medication or food (Figure 
2). Of them 96 (47.3%) were informed by the prescribing physician and 52 (25.6%) 
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by the community pharmacy. Further information sources were package inserts (24; 
11.8%), hospital (7; 3.4%), home care nurses (2), magazines (2), friends (2) and 
television (1). In two cases the customers themselves were health care 
professionals. The remaining 17 patients could not remember of whom they were 
informed about potential drug interactions. 
The level of information varied between customers with different POM therapies: 22 
of 23 (95.6%) immunosuppressed, 88 of 134 (65.7%) anticoagulated customers, 9 of 
17 (52.9%) treated with MAO-inhibitors, 51 of 82 (62.2%) customers treated with 
tetracyclines, 12 of 61 (19.7%) treated with potassium-sparing diuretics and 21 of 
117 (17.9%) treated with low-dose ASA reported having been informed about the 
problem (Figure 2).  
The awareness was significantly higher for potential drug interactions classified as 
‘severe’ [OR 1.79; 95% CI 1.16, 2.77, P = 0.009]. Furthermore, regular customers 
aware of potential drug interactions were significantly younger [OR 0.95; 95% CI 
0.93, 0.97, p<0.0001]. For regular customers, no association between  awareness 
and gender [OR 1.05; 95% CI 0.70, 1.57, P = 0.818], recording of self-medication 
data by community pharmacies [OR 1.06; 95% CI 0.71, 1.59, P = 0.778], number of 
prescribed drugs [OR 1.03; 95% CI 0.92, 1.15, P = 0.599], occurrence of a potential 
drug interaction with an OTC drug purchased for self-medication [OR 0.92; 95% CI 
0.52, 1.61, P = 0.669] or occurrence of a potential drug interaction with another 
prescribed drug [OR 1.11; 95% CI 0.68, 1.81, P = 0.763] was found. 
In the pharmacies that partially recorded customers’ self-medication more patients 
were informed about potential drug interactions but the difference compared with 
customers of other pharmacies was not significant (chi-square, P = 0.534). 
Of the 69 regular customers with potential drug interactions between POMs and 
OTC-drugs for self-medication, 33 (47.8%) reported knowing about the potential drug 
interactions.15 of them specified that their physician or pharmacist alerted them and 
precautions were taken. 
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Discussion 
This study focuses on selected potential drug interactions of varying clinical 
relevance and with different management options (Table 1) in two different groups of 
pharmacy customers: (A) passer-by customers whose prescribed drug therapy is not 
known and (B) regular customers whose prescribed drug therapy is usually recorded. 
This reflects the daily practice in community pharmacies. However, only a selection 
of potential drug interactions was investigated. Therefore, the overall prevalence of 
potential drug interactions with self-medication is certainly higher. 
Of 102 passer-by customers purchasing one of the selected OTC drugs (Table 1) 
only 3 reported receiving treatment with a potentially interacting POM. All of the 
potential interactions were of moderate severity. A study in Finland revealed similar 
results with a low prevalence of 4% of harmful potential drug interactions in OTC 
drug users [3]. In contrast, the prevalence of selected potential drug interactions in 
the population of regular customers treated with selected POMs with a risk for 
potential drug interactions with OTC drugs was relatively higher (15.9%). A reason 
for the low prevalence of potential drug interactions in passer-by customers might be 
that they do not regularly consume drugs. It is difficult for community pharmacists to 
identify and manage potential drug interactions in passer-by customers because of a 
lack of information about their medication profile and their purchase of drugs for self-
medication in different pharmacies. Focus on regular customers treated with selected 
POMs known to interact with OTC drugs may be a helpful strategy in community 
pharmacies. Honig and Gillespie [12] proposed useful strategies for avoiding 
potential drug interactions between OTC-drugs and POMs on both individual and 
societal levels. They suggested better labeling of drugs and highlighted the need to 
enquire about OTC-drug use. Of the regular customers, more than half (53.2%) had 
no information on potential drug interactions between their POMs and OTC-drugs. As 
expected, poor awareness was particularly marked for potential drug interactions of 
moderate severity.  
In 8 of the 14 participating community pharmacies partial self-medication records 
were held for their regular customers. This service is recent and currently only few 
customers are covered. Wider implementation of this service would be useful. A 
precondition is the customer’s acceptance of surveillance by his pharmacy. Therefore 
customers have to be motivated to participate more fully in their healthcare [17]. 
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The severity of a potential drug interaction can have a significant effect on 
identification and its management. Hansten, Horn and Hazlet suggested a new 
classification of potential drug interactions based on management options [18]. The 
implementation of this classification in computerised drug interaction systems could 
reduce the override of alerts of less severe potential drug interactions and improve 
their management by health-care professionals. Our results suggest the need for 
optimised tools and approaches for the identification and management of potential 
drug interactions in community pharmacies, the only place where a check for both 
POM and OTC drugs can be systematically performed. 
 
Regular customers reported taking OTC drugs infrequently. Those taking analgetics 
(NSAIDs or ASA) for self-medications were particularly likely to mention use of their 
drugs only in case of need and therefore less than ‘daily’. Another study supports our 
results suggesting that participants took OTC analgetics mainly temporary: Only 7% 
of the study population used OTC drugs daily [3]. This occasional ingestion of OTC 
drugs for self-medication reduced the risk of dose-or time-related interactions [19] 
such as interactions between low-dose ASA with ibuprofen or interactions between 
tetracyclines and polyvalent cations. For other dose- or time-related potential drug 
interactions the situation is different: Patients treated with POMs such as oral 
anticoagulants or immunosuppressants that require regular monitoring, even the 
occasional ingestion of potentially interacting OTC drugs should be avoided because 
of an unfavorable risk benefit ratio. For drug interactions such as between MAO-
inhibitors and dextromethorphan or sympathomimetics (Table 1) an infrequent intake 
still present a substantial risk.  
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Conclusion 
In conclusion, this study reveals that potential drug interactions between POMs and 
OTC drugs for self-medication are widespread. Efforts to increase awareness of 
potential drug interactions are needed. Although community pharmacies are 
equipped with a computerised check system for potential drug interactions this is 
often not applied to self-medication. Vigilance for all drugs, including those sold over 
the counter should be improved. There is a particular need for improved checking for 
drug interactions. Customers should be asked regularly about their self-medication to 
prevent serious interactions with prescribed medication. 
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Tables 
Table 1: Selected potential drug interactions between prescription only medicines and over-the-counter drugs or food 
Potential drug interaction 
Prescription only medicine 
Over-the-counter drug or 
food Class1 Possible adverse outcome2 Management options2 
Orally-administered tetracycline  
(Doxycyline, Lymecycline, 
Minocycline)3 
Polyvalent Cations (e.g. 
Aluminium, Calcium, Iron, 
Magnesium, Zinc)  
moderate Impaired absorption of the tetracycline can 
reduce the serum concentration and the 
antibacterial efficacy of the tetracycline 
Minimise risk by coordinated sequence of 
administration (take tetracyclines 2 hours before or 6 
hours after polyvalent cations) or consider an 
alternative antibiotic 
Low-dose ASA4 Ibuprofen minor Inhibition of the antiplatelet effect of ASA 
and possible decrease of its cardioprotective 
effects 
Minimise risk by coordinated sequence of 
administration (ibuprofen ingestion 2 hours after ASA) 
or consider an alternative to ibuprofen  
Potassium salts severe severe hyperkalaemia  Avoid unless benefit outweighs risk in cases of severe 
or refractory hypokalaemia and minimise risk by 
carefully monitoring serum potassium levels 
Potassium-sparing diuretic 
(Eplerenone, Potassium 
canreonate, Spironolactone, 
Triamteren)3 
NSAIDs5 moderate Hyperkalaemia, renal impairment, renal 
failure 
Minimise risk by monitoring serum potassium levels 
and renal function 
NSAIDs5 moderate Oral Anticoagulant 
(Acenocoumarol, 
Phenprocoumon)2 Salicylates severe 
Bleeding due to inhibition of platelet function 
and gastric erosions 
Avoid unless benefit outweighs risk, monitor the 
prothrombin time carefully and watch for evidence of 
bleeding especially from the gastrointestinal tract 
St. John‘s wort moderate Decreased effect of immunosuppressant, 
rejection reaction 
Usually avoid and use antidepressant other than St. 
John‘s wort, if used together monitor for altered 
immunosuppressant effect by initiation, discontinuation 
or changes in dosage of St. John‘s wort preparations 
Immunosuppressant1 
(Cyclosporine, Sirolimus, 
Tacrolimus)3 
 
Grapefruit minor Increased blood concentration of the  
immunosuppressant, nephrotoxicity 
Avoid drinking grapefruit juice. If grapefruit juice is 
taken concurrently carefully monitor for altered 
immunosuppressant effect especially by initiation, 
discontinuation of grapefruit juice  
Dextromethorphan  severe Serotonin syndrome (agitation, confusion, 
hypomania, myoclonus, rigidity, 
hyperreflexia, tremor, incoordination, 
sweating, shivering, seizures, coma) 
Dextromethorphan is contraindicated in patients 
receiving nonselective or MAO-A inhibitors 
(Moclobemide)  
Monoamino oxidase inhibitors 
(Moclobemide, Selegiline)3 
Indirect-acting 
Sympathomimetics 
(e.g. Phenylephrine, 
Pseudoephedrine) 
severe Hypertension, palpitations, headache and 
lightheadedness 
Avoid combinations and use alternative therapies 
1Classification according to the database Pharmavista® 51, which is used by Swiss community pharmacies drug interaction surveillance software 
2Retrieved from Drug Interactions: Analysis and Management 85 and the database Pharmavista® 51  
3Drugs available in Switzerland 
4ASA = Acetyl salicylic acid, 5NSAID = Non-steroidal anti-inflammatory drug  
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Table 2: Questions asked in the structured telephone interview with regular customers 
 
Question Possible Answers 
Are you informed about possible drug interactions4 of your 
POM3 with OTC-drugs?  
Yes / No  
If yes, who did inform you? My pharmacist / my physician / the drug information 
prospect / further possibilities 
Did you take one of following1 OTC2 drugs or foods during 
therapy with the POM3? 
Yes / No 
 
How often do you take the potentially interacting OTC 
drug?  
Several times per day / daily / several times per 
week / less often 
Was the potential drug interaction detected?  Yes / No  
If yes, by whom? My pharmacist / my physician / the customer 
himself / further possibilities 
Was one of the following actions5 taken to minimise the 
risk of an adverse event? 
Choice of an alternative therapy, stop of one drug, 
time or dose adjustment, laboratory monitoring, 
further actions 
Did one of following possible outcomes (listed in Table 1) 
occur? 
Yes / No  
1: Potentially interacting OTC drugs are listed in Table 1 
2: OTC = Over-the-counter 
3: POM = Prescription only medicine 
4: Potential drug interaction = potential drug-drug or drug-food interaction 
5: Management actions to minimise risk an adverse effect retrieved from Drug Interactions: Analysis and 
Management 85 
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Figure 1: Prevalence of potential drug interactions in regular customers of community pharmacies 
treated with selected prescription only medicines 
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Figure 2: Awareness of potential drug interactions of regular customers of community pharmacies 
treated with selected prescription only medicines 
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Abstract  
Objective:  
To analyze the current drug interaction management in Swiss community pharmacies 
with a particular focus on electronic systems and to compare the results with those 
expressed by German general practitioners in a recent survey. 
 
Methods:  
Data were collected with a postal questionnaire which was randomly sent to 500 out 
of 833 community pharmacies of the German part of Switzerland. 
 
Results:  
The response rate was 57.4% and only 24.7% pharmacists reported to be confronted 
less than daily with potential drug interactions. Use of computer software to identify 
potential drug interactions was widespread in community pharmacies (90.2%) and 
the software was the primary source of information (81.2 ± 29.6%). The quality of the 
interaction software was judged sensitive (identifying all dangerous interactions) by 
80.5 ± 21.5% but specific (identifying only relevant interactions) by only 38.3 ± 32%. 
Pharmacists declared a low override rate (14%) of drug interaction alerts although 
unjustified alerts were reported by 60.6 ± 33.1%. In contrast to general practitioners 
pharmacists opted less often for information on the mechanism of the interaction and 
more frequently for details for dose adjustment. Both groups complained about 
deficient information on non-interacting alternatives. 
 
Conclusion:  
The information needs of community pharmacists differed considerably from general 
practitioners and pharmacists were overwhelmed by inappropriate alerts because of 
a lack of specificity of their drug interaction systems. Substantial improvement of drug 
interaction software systems is thus required at least in two important aspects, the 
suppression of inappropriate alerts and the tailoring to the needs of the user. 
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Introduction 
Potential drug interactions are highly prevalent, but the number of adverse drug 
reactions caused by drug interactions is probably low [1-4]. Reported incidences in 
outpatients range from 9.2% to 70.3% for drug interactions of any severity and from 
1.2% to 23.3% for those considered of major relevance [5-11]. A German primary 
care study showed that of all observed major or moderate potential drug interactions 
only 11.7 % offered no management options and such drug combinations should 
thus be avoided [12]. The majority of the potential drug interactions do not result in 
clinical manifestations if they are managed adequately e.g. by dose adjustment or a 
coordinated sequence of administration [12]. However, given the frequency of 
combination treatment even a low penetrance of complications caused by drug 
interactions will substantially impact drug safety. Indeed drug interactions are 
responsible for up to 3.8% of hospital admissions [2, 13-15]. 
 
In some countries, including Switzerland, community pharmacies are obliged to keep 
a medication history of all dispensed prescription drugs and to check prescriptions to 
prevent the use of unsafe drug regimens including those caused by potentially 
interacting drugs. To comply with these statutory requirements, almost all 
pharmacies use computer software systems for the quality assurance of 
pharmacotherapy. These systems identify potential drug interactions, alert the 
pharmacy team to intervene before dispensing potentially interacting drugs, and 
serve as a drug interaction information source. 
 
Thus far, only very few epidemiologic studies on the adverse outcomes of drug 
interactions have been performed. Therefore drug interaction information sources 
generally lack data on clinical importance of potential drug interactions and 
information on risk factors that contribute to their adverse outcomes. Indeed the 
majority of general practitioners were dissatisfied with the information on therapeutic 
alternatives, severity, mechanism, and dose adjustment in the drug interaction 
information sources they used [16]. Consequently electronic drug interaction 
information sources should include management guidelines for dose adjustment and 
spacing of administration times and should help to avoid contraindicated drug 
combinations. Moreover, they should also provide monitoring information for an early 
detection of adverse events. 
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Drug interaction information is required on different levels of drug therapy. First, the 
prescription of drug combinations should be supported by appropriate information 
technology to maintain high quality standards already at the point of care. In addition 
to the support of physicians in drug selection and dosing also the dispensing 
pharmacies should have access to comprehensive information on drug interactions in 
order to assess combinations prescribed by several independent physicians in 
charge of a patient and also to detect risks arising from combinations with drugs 
dispensed without prescription. Obviously, safety concerns detected in a pharmacy 
should be resolved in communication with the treating physician who ideally has 
access to the same knowledge bases. Because pharmacists and physicians have 
different duties in pharmacotherapy and also different training, their information 
needs may also differ. We therefore aimed to assess how pharmacists deal with drug 
interactions in daily practice, which information sources they use and wish to have, 
and how their requirements relate to those expressed by general practitioners. 
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Methods 
Study population 
From the 833 pharmacies in the German speaking part of Switzerland a random 
sample of 500 community pharmacies was invited to participate in this cross-
sectional survey. Pharmacies were selected by use of the freeware Research 
Randomizer (http://www.randomizer.org/form.htm). No stratification or any other 
selection procedures were applied.  
 
In Switzerland community pharmacies dispense 68.9% of all over-the-counter drugs 
and 57.2% of all prescription drugs. The remaining drugs are dispensed by 
physicians (27.8%), hospitals (13.9%), and drug stores (1.2%) [17]. If not limited by 
regional legislation, physicians are allowed to store drugs in their practice and 
dispense drugs to their patients. 
 
All Swiss community pharmacies have electronic drug management systems. The 
knowledge base on drug interactions integrated in these systems is originally 
developed by ABDATA (Eschborn, Germany) [18] to be used in all Austrian, German, 
and Swiss community pharmacies. The knowledge base is adapted by E-mediat AG 
(Schönbühl, Switzerland) to the Swiss market and sold to pharmacy software 
providers. Furthermore, it is published as an integrated part of Pharmavista® [19], a 
drug information service which is available on the Internet or on CD-ROM as 
subscription-only service for Swiss health care professionals. Each drug interaction 
monograph is fully referenced and monthly updated. Potential drug interactions are 
classified into ‘severe’ (life-threat / intoxication / permanent harm), ‘moderate’ 
(frequent therapeutic problems / combination can be administered but close 
monitoring required), ‘minor’ (increased or decreased drug effect / only specific 
subgroups affected), ‘negligible’ (no or limited clinical effects / generally no 
modification of therapy required) and ‘external specifications’ (only occurring in 
particular cases / clinical consequences unclear). The majority of electronic drug 
interaction systems used in Swiss community pharmacies can be set up to flag only 
potential drug interactions of moderate and/or high severity. Such alerts can either be 
‘ignored’ (overridden); ‘considered’ (deliberate response to the alert), or in some 
cases have to be ‘analysed’ more precisely through consideration of additional 
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parameters (e.g. patient related risk factors) and consultation of drug interaction 
information sources. 
 
Data collection 
The questionnaire included 28 items grouped in four sections. The first part of the 
questionnaire contained three questions to clarify pharmacists’ perceptions of drug 
interactions and the preoccupation with this problem in daily practice. The second 
part focused on management of interaction alerts in pharmacy practice with three 
questions on the configuration of the drug interaction surveillance software, three 
questions on the quality of their drug interaction surveillance software to be ‘sensitive’ 
(software identifies % of cases of dangerous potential drug interactions) and to be 
‘specific’ (software identifies % of cases of really clinically relevant potential drug 
interactions) and to flag ‘false’ alerts (e.g. multiple or repeated alerts for the same 
patient, the patient was no longer taking the interacting drug, in % of cases) and four 
questions on the actions taken by pharmacy teams after drug interaction alerts. A 
third part contained five questions on the usage (frequency and type) of drug 
interaction information sources and the pharmacists’ satisfaction with the provided 
information. Eight questions in the fourth part addressed the communication with 
physicians. Additionally, characteristics of the pharmacists (gender, professional 
experience, working hours, postgraduate education) and their community pharmacies 
(location, profile of customers, and implementation of quality management system) 
were assessed. We used multiple choice questions or visual 
analogue scales ranging from never (coded as 0%) to always (coded as 100%). 
 
Questions on pharmacists’ perception of the risk arising from potential drug 
interactions, the preoccupation with potential drug interactions in daily practice, the 
usage (frequency and type) of drug interaction information sources, and their 
satisfaction with the information provided were retrieved from a recent structured 
questionnaire-based survey among German general practitioners [16].  
 
The study was carried out between June 2005 and August 2005. The questionnaire 
was sent together with a letter explaining the rationale of the study and a prestamped 
return envelope. Questionnaires had to be filled in by the pharmacy manager or his 
substitute. Comprehensibility of the questionnaire was evaluated in a pre-test among 
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10 community pharmacists. To increase the response rate, responders could win one 
of five annual subscriptions to an educational community pharmacy drug information 
service (value = 40 EUR). Four weeks later, a reminder was sent together with a 
second questionnaire to non-responders of the survey to further boost response 
rates [20]. To characterise non-responders, gender, age, professional experience, 
configuration of the drug interaction surveillance software settings, and reason for 
non-response were assessed in a telephone interview with 50 randomly selected 
non-responding pharmacy managers. 
 
All returned questionnaires were processed with the automated forms processing 
software Teleform® version 7.0 from Cardiff Software Inc., Vista, USA. Automated 
forms processing software was validated by Jorgensen et al. [21] who showed an 
improved quality of the data while reducing the processing time. To avoid potential 
errors, all numeric and letter recognitions were verified visually on data sheets and 
on screen. 
 
Data analysis 
Results are expressed as proportions and as means ± standard deviation (SD) or 
medians with the 25% to 75% interquartile range (IQR). Main descriptive results are 
expressed as absolute numbers and percentages. Independent two-sample 
comparison of single variables was analysed using Students’ t-test. Chi-square 
statistics was used for categorical comparisons. In a multiple logistic regression 
analysis the daily preoccupation with potential drug interactions or the frequency of 
using drug interaction information sources as dependent variables were 
dichotomised into ‘‘daily’’ (for each prescription, several times daily, daily) versus all 
other categories (once a week, once a month, less than once a month, never). 
Covariates were gender, professional experience, working hours [%], pharmacy 
certified for quality management, pharmacy location at countryside or village, 
predominantly change customers, postgraduate education as community pharmacist, 
the pharmacies` software configuration to flag only ‘severe’ potential drug 
interactions, and software configuration of the length of the period a patient’s past 
medication history was screened for potential drug interactions. Odds ratios (OR) are 
presented with 95% confidence intervals (CI). Statistical significance was defined as 
Project C: Management of drug interactions in community pharmacies 
 86
a p-value <0.05. All statistical analyses were performed using SPSS for Windows 
version 13.0 (SPSS, Inc, Chicago, IL, USA). 
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Results 
Characteristics of the study sample 
Of 500 invited community pharmacies 57.4% (287) returned the questionnaire. Most 
questionnaires (87.1%, 250/287) were filled in by the pharmacy manager. More than 
95% of the questions were answered by all responders. Characteristics of the 
responding pharmacists and their community pharmacies are presented in Table 1. 
Comparison of responding pharmacy managers with 50 non-responding pharmacy 
managers showed no significant differences with respect to gender (p=0.54), mean 
age (p=0.56), professional experience (p=0.47), and the location of their community 
pharmacies (p=0.36). The main reasons for non-response were lack of time or 
interest (34%) and personal absence during the survey period (26%). 
 
Perception of the risk arising from drug interactions and preoccupation with 
potential drug interactions 
For the majority of the responding pharmacists [91% (261/287)] drug interactions 
were an important safety hazard in pharmacotherapy. Of these, 19.5% (51/261) 
judged the clinical relevance of drug interactions to be an outstanding problem, 
76.2% (199/261) to be equally important, and only 4.2% (11) to be subordinate 
compared with other safety hazards in pharmacotherapy. Neither a significant 
association with gender or postgraduate specialisation in community pharmacy nor a 
trend with age, workload, or years of professional experience was found (p>0.05). 
The majority (75.3%; 216/287) of the responding pharmacists mentioned to deal at 
least daily with potential drug interactions. 
 
Configuration and perception of the quality of drug interaction surveillance 
software 
The community pharmacies’ computers were equipped with pharmacy software of 6 
different providers and most of them (90.2%; 259/287) used their software to identify 
potential drug interactions. In contrast, 9.8% (28/287) had inactivated this option in 
their computer system. Those pharmacies were less frequently certified with a quality 
management system (p=0.032) and felt less frequently confronted with potential drug 
interactions (p<0.001). In 18.5% (48/259) of the community pharmacies the drug 
interaction surveillance software was set to flag only ‘severe’, in 39.8% (103/259) to 
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flag ‘severe’ and ‘moderate’, and in 41.7% (108/259) to flag all potential drug 
interactions. In pharmacies in which the software was set to flag only ‘severe’ 
potential drug interactions, pharmacists less frequently dealt with potential drug 
interactions (p<0.001). The median length of the period a patient’s past medication 
history was screened for potential drug interactions was 120 days (IQR 90-180 days). 
Pharmacists estimated the quality of their drug interaction surveillance software to be 
‘sensitive’ in 80.5 ± 21.5%, to be ‘specific’ in 38.3 ± 32%, and to flag ‘false’ alerts 
(e.g. multiple or repeated alerts for the same patient, the patient was no longer taking 
the interacting drug) in 60.6 ± 33.1% of drug interaction alerts. If the software was set 
to flag only ‘severe’ potential drug interactions, pharmacists (n = 259) rated their drug 
interaction surveillance software to be less ‘sensitive’ (72.1 ± 27.0% vs. 82.6 ± 
19.5%; p=0.018) but more ‘specific’ (54.7 ± 36.7% vs. 34.8 ± 29.8%; p=0.002). When 
pharmacists estimated the software to produce ‘false’ alerts in ≥ 50% (n=169) of 
alerts their software was configured to observe a significantly longer period of the 
medication history (170.5 ± 97.8 days vs. 133.1 ± 82.3 days; p=0.007). Multiple 
logistic regression analysis confirmed these results: Configuration of the pharmacy 
software to flag only ‘severe’ potential drug interactions (OR 0.009, 95% CI 0.003, 
0.028; p<0.001) and the configuration of the length of the period a patient’s past 
medication history was screened for potential drug interactions (OR 1.014, 95% CI 
1.003, 1.025; p=0.014) were associated with the daily preoccupation with potential 
drug interactions, while no effect was observed with all other defined covariates (see 
Methods). 
 
Management of drug interaction alerts by community pharmacy teams 
Written directives for the management of flagged drug interaction alerts were 
available in 18.5% (48/259) of the community pharmacies while 78.4% (203/259) 
reported to have only verbal instructions. Pharmacists estimated that drug interaction 
alerts are always ‘considered’ in 86 ± 18.6% of cases by their pharmacy teams. This 
proportion was not higher if the drug interaction surveillance software was configured 
to flag only ‘severe’ potential drug interactions (p=0.19). Pharmacists estimated that a 
more thorough follow-up ‘analysis’ of drug interaction alerts through consultation of 
further information sources was required in 63.8 ± 32.7% of the alerts. This frequency 
was higher if the drug interaction surveillance software was configured to flag only 
‘severe’ potential drug interactions (p<0.001). 
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Of all community pharmacies 79.8% (229/287) documented activities triggered by the 
detection of potential drug interactions. Of them 36.2% (83/229) stated to document 
their activities only if a ‘severe’ potential drug interaction was flagged, 20.1% (46/229) 
only if a physician was contacted, 30.1% (69/229) only if the therapy was modified 
(e.g. closer monitoring, dose adjustment, or alternative therapy), and 11.8% (27/229) 
in any situation. Furthermore, pharmacists estimated that in their pharmacies 70.8 ± 
28.1% of the customers are informed about potentially interacting drugs. 
 
Perception of use and quality of drug interaction information sources 
In case of consultation of drug interaction information sources to analyse more 
precisely an alert or to answer a specific question, pharmacists indicated to favour 
drug interaction information provided by their electronic drug interaction system in 
81.2 ± 29.6% and the published national drug formulary [22] in 67.2 ± 32% of the 
cases. More male pharmacists reported to use preferentially (i.e. in ≥ 50% of cases) 
electronic drug interaction information sources (community pharmacies drug 
interaction surveillance software, the drug interaction knowledge base of 
Pharmavista® [19], or further specific electronic drug interaction information sources 
available via internet or from their local computer or personal digital assistant 
software (e.g. DRUGREAX© Thompson Micromedex™, Greenwood Village or 
Stockley’s Drug Interactions, Electronic Version 2006 © The Pharmaceutical Press, 
London, etc.) (p=0.05). In general, 70.3% of the pharmacists (199/283) reported to 
use their drug interaction information sources ‘daily’. 
Multiple logistic regression analysis did not show an association between the ‘daily’ 
use of drug interaction information sources and defined covariates (see methods). 
Figure 1 and Figure 2 show satisfaction with the content provided by the drug 
interaction information sources currently used and the expectations with respect to 
the content of future drug interaction information sources. The use of the same 
questions asked in a recent survey in general practitioners [16] enabled direct 
comparison of responses of community pharmacists with those of general 
practitioners. Congruently, community pharmacists and general practitioners were 
most dissatisfied with the content of their drug interaction sources about non-
interacting alternative therapies. Both equally considered the severity of the outcome 
to be an essential information, but all other comparisons of pharmacists’ and general 
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practitioners’ satisfaction and future expectations differed significantly (p<0.001) 
(Figure 1 and Figure 2). 
 
Communication between pharmacists and prescribing physicians concerning 
potential drug interactions 
Pharmacists reported a median of 25 (IQR 10-30) overall contacts to prescribing 
physicians and a median of 3 (IQR 1-6) due to potential drug interactions during the 
three months preceding the survey. A total of 56.8% (163/287) pharmacists reported 
to contact physicians in general exclusively by telephone, the remaining 43.2% 
(124/287) by telephone or fax, video conferencing, email, mail, or via the patient. If 
the contact was induced by a potential drug interaction most of the pharmacists 
(72.5%, 208/287) chose the direct communication by telephone. 
 
Pharmacists’ perception of the frequency of causes to contact a physician is 
presented in Figure 3. The majority of pharmacists (62.7%; 180/282) reported to 
contact physicians ‘rarely’ or ‘never’ due to potential drug interactions. Pharmacists 
working in pharmacies whose drug interaction surveillance software is configured to 
flag only ‘severe’ potential drug interactions reported similar frequencies (72.9%; 
35/48) to contact a physician ‘never’ or ‘rarely’ compared with the other pharmacists 
(61.2%; 126/208) (p=0.128). 
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Discussion 
The use of computer software for prospective medication surveillance is a very 
common approach to avoid medication errors [1]. In our study all community 
pharmacies were equipped with drug interaction surveillance software and most of 
them (90.2%) used it to identify potential drug interactions. Electronic drug interaction 
checks in community pharmacies and physician offices can reduce the dispensing of 
prescriptions with severe interactions up to 67.5 % [23]. Although immediate impact 
on prescription and dispensing has been demonstrated, there is only limited and 
inconclusive evidence whether the computer software is effective enough to prevent 
medication errors [24-26]. Evaluation of the performance of pharmacies’ electronic 
drug interaction systems in the USA showed that they largely varied in specificity and 
sensitivity to identify clinically important potential drug interactions in daily practice 
[27]. 
 
In our survey pharmacists reported to consider 86% of interaction alerts and hereby 
admit to in fact ignore 14% of them. This override is comparable with 22% of 
physicians who admitted to ignore alerts without considering more information on the 
drug interaction [28]. With respect to other studies revealing that physicians and 
pharmacists override the majority of electronic alerts in primary care [29, 30] this rate 
seems small. A major reason for ignoring such alerts may be that too many alerts 
considered irrelevant are provided [31, 32]. Consequently, electronic drug interaction 
systems can be configured to flag only ‘severe’ potential drug interactions. Such a 
configuration was used by 18.5% of responding pharmacists. As expected, in these 
pharmacies the preoccupation with drug interactions was reduced, drug interactions 
were more frequently further evaluated, and the pharmacists acknowledged that their 
electronic drug interaction system may be less ‘sensitive’ while being more ‘specific’. 
 
The approach to filter potential drug interactions by computer systems is 
indispensable and a promising way to reduce the overwhelming fraction of 
meaningless alerts. Indeed, Bergk and co-workers [12] showed that their incidence 
could be reduced by 28% when filtering the fraction of minor and unspecified 
potential drug interactions. However, the resulting prescription quality strongly 
depends on the classification of the severity of potential drug interactions and still 
ignores patient characteristics which could render a ‘severe’ interaction ‘minor’ for an 
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individual patient. Moreover, the very high number of 60% ‘false’ alerts (e.g. multiple 
or repeated alerts for the same patient, the patient was no longer taking the 
interacting drug) reported in our survey indicates that also the timing of drug therapy 
needs to be considered by the interaction software in more detail. Moreover, because 
many drug interactions are concentration-dependent and can be avoided by 
appropriately adjusting doses [12] optimised drug interaction systems should also 
include an alert suppression if an interacting combination is prescribed in adjusted 
doses. Hence, more sophisticated filters instead of unjustified filters to flag only 
potential drug interaction of highest severity are needed. Indeed, Peng and 
coworkers [33] reported that sophisticated filters (assessment of time overlapping of 
drug therapies, of duration of drug therapy, and of total drug dose) could reduce the 
incidence of potential drug interaction alerts by 71% and in combination with clinical 
pharmacists’ review even by 94%. Consequently, software providers should be 
challenged to revise and optimise the current drug interaction surveillance software 
and also include an alerting history in their software because many alerts are caused 
by already checked repeat prescriptions and therefore are likely overridden [29, 30, 
34]. 
 
Pharmacists most frequently sought information on drug interactions in their 
electronic surveillance system even though it did not meet their expectations in most 
important aspects. Particularly, most pharmacists complained about a lack of 
information about non-interacting alternative therapies and the specific advice for 
dose adjustment. General practitioners expressed the same criticism [16]. In 
agreement, Hansten et al. [27, 31] noticed that management guidelines provided by 
drug interaction information sources are often inadequate and should be considered 
in the classification of potential drug interactions. 
 
With regard to the content of future drug interaction information sources community 
pharmacists and general practitioners expressed very different expectations with the 
largest difference seen in the valuation of information components on advice for dose 
adjustment and non-interacting alternatives which were less essential for community 
pharmacists. This result reflects the different situations and needs of the two 
professions in daily practice. 
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In comparison with further reasons to contact a physician potential drug interactions 
play an inferior role (Figure 2). The relatively low frequency of contacts (one per 
month) with respect to the high frequency of alerts and the statement that the 
majority of their patients is informed about the detected drug interactions indicates 
that in the process of prescribing and dispensing community pharmacies manage 
drug interaction alerts mainly themselves. This raises the question on relevance and 
quality of this management. 
 
Some limitations of this survey merit discussion. First, the overall response rate was 
only 57.4% making a non-response bias possible. However, this figure compares 
well with a recent survey in German general practitioners [16] and the fact that 
nonresponding pharmacists did not differ from responders suggests that such a bias 
will not be critical. Second, our study was conducted in the German-speaking part of 
Switzerland and represents the health care situation in this region in the year 2005. 
However, there are many reasons justifying extrapolation of its results to other 
European health care systems. Indeed, drug interaction software in community 
pharmacies from all German speaking countries (Switzerland, Germany, and Austria) 
is based on the same drug interaction database and in these countries also many of 
the software systems used by the physicians have integrated this database. Because 
of the numerous similarities in drug prescription and dispensing in Switzerland and 
Germany it appears likely that the differences observed between the two professions 
rather relate to differences in their tasks and needs than differences between 
countries. It therefore supports the notion that for each profession specific tools 
should be developed. 
 
In conclusion, our study revealed that the drug interaction software supporting 
community pharmacists lacks sensitivity and specificity while producing a high rate of 
‘false’ alerts. The study also showed that the information needs of community 
pharmacies differed considerably from those of general practitioners. Hence, 
substantial improvement of drug interaction software systems is required at least in 
two important aspects, the suppression of inappropriate alerts and the tailoring to the 
needs of the user. 
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Table 1: Characteristics of the participating pharmacists and their pharmacies (N=287)  
 
Characteristics of pharmacists 
Mean age ± SD 45.0 ± 9.4 years 
Female gender 147 (54.8%) 
Mean years of professional experience ± SD 18.5 ± 9.5 years 
Mean working hours  ± SD [%] 90 ± 15% 
Pharmacy manager 250 (87.1%) 
Postgraduate specialisation as community pharmacist 215 (74.9%) 
Characteristics of community pharmacies 
Location 
 City or urban agglomeration 
 Countryside or village 
 
200 (70%) 
86 (30%) 
Predominantly regular customers (versus change customers) 212 (74.4%) 
Implementation of quality management system  
Implemented  
Submitted for certification 
No quality management system 
 
27 (9.4%) 
83 (28.9%) 
176 (61.3%) 
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Figure 1: Swiss pharmacists’ and German general practitioners’ satisfaction with the content 
provided by the drug interaction information sources they currently use.  
 
Comparison of the results of two questionnaire surveys in 287 pharmacists and 1216 general 
practitioners. 
 
N = Number of responding pharmacists and general practitioners  
P-value: Chi-square analysis of differences between responses of pharmacists and general 
practitioners who answered that the content provides insufficient information.  
 
 
 
 insufficient information     sufficient information 
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Figure 2: Swiss pharmacists’ and German general practitioners’ expectations with respect to 
the content of future drug interaction information sources. 
 
Comparison of the results of two questionnaire surveys in 287 pharmacists and 1216 general 
practitioners by chi-square analysis. 
 
N = Number of responding pharmacists and general practitioners  
P-value: Chi-square analysis of differences between responses of pharmacists and general 
practitioners who expected that the content is essential.  
 
 
 essential     desirable, but not absolutely necessary     dispensable 
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Figure 3: Reasons to contact a physician as indicated by 287 Swiss pharmacists in a 
questionnaire survey. 
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Summary  
Background and objective:  
Drug interaction alert systems are commonly used in community pharmacies to 
identify potential drug-drug interactions. However, depending on the software default 
setting, pharmacists may override alerts because they are too numerous. We 
explored the handling of drug interaction alerts by community pharmacies in 
Switzerland. 
 
Methods:  
Data were collected by 15 pharmacy students in 15 Swiss community pharmacies. 
The medication history and the drug interaction alerts of 600 patients who had ≥ 2 
drugs on prescription were assessed, and the pharmacists in charge were 
interviewed about their management of drug interaction alerts.  
 
Results:  
In the 15 study pharmacies, the computer systems were programmed to flag only 
‘severe’ drug interactions in 4, ‘severe or moderate’ in 6, or ‘severe, moderate or 
minor’ in 5 pharmacies. The median frequency of drug interaction alerts increased 
with decreasing default severity level from 0.5 to 40 respectively to 76 per 40 patient 
visits and pharmacy. Due to these default settings, 277 (35.2%) of 787 potential drug 
interaction alerts on new or repeated prescriptions were overridden by computer 
systems. Only 256 (32.5%) of 787 potential drug interactions emerged from new 
prescriptions. The alert systems produced 656 alerts of which 146 were irrelevant 
due to multiple alerting of the same interaction or of drug combinations currently no 
longer taken. Of the 510 remaining relevant drug interaction alerts, 289 (56.7%) were 
overridden by community pharmacists without any action taken. If the pharmacist 
took care of a patients’ prescription him- or herself (as opposed to just controlling a 
prescription after a technician took care of the patient), fewer drug interaction alerts 
were overridden by the pharmacist (Odds ratio [OR] 0.6, 95% confidence interval [CI] 
0.42 – 0.98; p=0.042). Both technical override (by default settings) and pharmacists’ 
decision to override alerts summed up to a total of 71.9% overrides (566 of 787 
potential drug interactions). Of the remaining 211 interactions alerts, 87 (41.2%) were 
checked more closely by consulting literature, contacting the prescribing physician or  
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discussing the issue with the patient. This led to 55 (63.2%) interventions (close 
monitoring, adjustment of dose or ingestion time, therapy stop, or switching to 
alternative therapy). Determinants associated with action taken after an interaction 
alert were the potential high severity (severe or moderate) (OR 3.34, 95% CI 1.77-
6.31; p<0.001) as well as the alert flagged for the first time (OR 3.76, 95% CI 1.98-
7.14; p<0.001). All severe potential drug interactions (N=10) generated an alert and 
all caused an intervention. 
 
Conclusions:  
Pharmacists override a substantial proportion of drug interaction alerts of minor or 
moderate potential severity by ignoring them or by programming the system to only 
flag drug interactions of potentially high severity. More sophisticated systems with 
improved sensitivity and specificity are required. As long as they are not available, it 
is important to ensure that at least potentially severe drug interactions are not 
missed, a goal that seems to be largely achieved.  
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Background 
Community pharmacists can play an important role in improving drug therapy by 
preventing the use of unsafe or non-effective drug regimens and by avoiding drug 
interactions with potentially harmful effects on patients [1]. To comply with this 
responsibility, community pharmacies in various countries, including Switzerland, 
fulfil the patients’ prescriptions, store an electronic medication history and use 
computer-assisted review tools. 
Drug interaction alert systems have already been proven to be effective in community 
pharmacies and in physician offices in reducing the number of potential drug 
interactions [2, 3[. A recent study revealed that between 20% and 46% of prescription 
drug claims were reversed when pharmacies were alerted for important potential 
drug interactions [4]. However, drug interaction alert systems in pharmacies have 
been shown to be too unsophisticated [5], leading to an excessive number of alerts 
which pharmacists or physicians find to be trivial or inappropriate for the current 
situation [6]. As a result, physicians and pharmacists override the majority of drug 
interaction alerts in primary care [7-9]. In a questionnaire survey among physicians, 
22% admitted to frequently override drug interactions alerts without properly checking 
them [10]. A common way to reduce the perceived excess number of interaction 
alerts is to activate by default only a subset of the entire drug interaction database, 
for example only drug interactions flagged with the highest level of potential severity. 
In a recent questionnaire survey most Swiss community pharmacists (90.2% of those 
who responded) reported to regularly use drug interaction alert systems [11]. A 
majority (58.3%) configured their system to flag only moderate to severe potential 
drug interactions thought to be clinically relevant. Nevertheless, they reported a lack 
of specificity of their drug interaction alert systems, and they reported to override only 
a low rate (14%) of drug interaction alerts. 
 
With the present study we aimed at further exploring the self reported drug 
interaction alert management of a sample of community pharmacies in Switzerland. 
In particular, we focused on the nature of drug interaction alerts and on pharmacists’ 
handling them in daily routine. 
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Methods 
Study design, patients and data collection 
We recruited 15 pharmacy students who were in their 5th study year and who 
attended their externship in a Swiss community pharmacy. They received written 
instructions and specific training. Each student collected data from patients who 
presented a new or a repeat prescription which was delivered or at least double 
checked by the pharmacist on duty. Inclusion criteria of patients were age ≥ 18 years, 
multiple (>2) drugs prescribed and at least one prior visit at this pharmacy to pick up 
prescription drugs during the last 3 months. 
Patient records contained the patients’ age and gender, the drug history of the 
previous 3 months, and data on drug interaction alerts; potential drug interactions 
were identified if drugs were prescribed on the same or on separate prescriptions, 
and issued by the same or by separate physicians. 
After consecutive collection of 20 cases, the students interviewed the pharmacist on 
duty using a structured questionnaire (Figure 1). During this interview he confronted 
the pharmacist with all potential drug interaction alerts produced by the electronic 
system, and the student recorded the pharmacists’ management of these drug 
interaction alerts. In addition, the students assessed the default configuration of the 
drug interaction alert systems. 
 
The students were instructed to collect data, and the community pharmacists gave 
informed consent. All data were anonymised in the pharmacy prior to being analysed. 
Each student repeated data collection on another day when another pharmacist was 
on duty, aiming at collecting a sample of 40 records per pharmacy.  
 
The study was carried out in May 2005. All data (patient records and structured 
interviews) were processed with the automated forms processing (AFP) software 
Teleform® version 7.0 from Cardiff Software, Inc, Vista, CA, USA. AFP was validated 
by Jorgensen et al. [12] who showed that AFP software reduced processing time. 
Due to possible errors, all numbers and letters which were recorded were verified 
visually on data sheets and on screen. 
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Classification of potential drug interactions 
All contributing Swiss community pharmacies work with electronic drug management 
systems. The knowledge base on drug interactions integrated in these systems is 
Pharmavista® [13], a system from the German ABDA-Database [14] adapted to the 
Swiss market. Potential drug interactions are classified into ‘severe’ (life-threatening / 
intoxication / permanent harm), ‘moderate’ (frequent therapeutic problems / 
combination can be administered but close monitoring required), ‘minor’ (increased 
or decreased drug effect / only specific subgroups affected), ‘negligible’ (no or limited 
clinical effects / generally no modification of therapy required), and ‘external 
specifications’ (only occurring in particular cases / clinical consequences unclear). 
The majority of drug interaction alert systems used in Swiss community pharmacies 
can be set to flag only potential drug interactions of moderate and/or high severity. In 
this study, all potential drug interactions of severe, moderate or minor clinical 
relevance according to the interaction database in Pharmavista® were investigated. 
 
Statistical analysis 
Descriptive results are expressed as medians with the corresponding 25% to 75% 
interquartile range (IQR), or as proportions. Main descriptive results are expressed 
as absolute numbers and percentages. Numerical variables were tested for normal 
distribution using the Kolmogorov-Smirnov test. The non-parametric Mann-Whitney-U 
test was used for unpaired two-sample comparisons. Nominal data in independent 
groups were compared with Pearson chi-square analysis. Covariates associated with 
the override of drug interaction alerts were detected with multiple logistic regression 
analysis. Odds ratios (OR) are presented with 95% confidence intervals (CI). 
Statistical significance was defined as p-value <0.05. Statistical analysis was 
performed using SPSS for Windows version 13.0 (SPSS, Inc, Chicago, IL, USA). 
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Results 
Patient characteristics 
The study encompassed data on 600 outpatients recruited in 15 community 
pharmacies operating with the same drug interaction database. Of those, 324 
(54.4%) were female, their median age was 63 (IQR 50-75) years, and 275 (45.8%) 
were ≥ 65 years. They were treated with a total of 3522 drugs which corresponded to 
10,556 possible drug pairs. For each patient a median of 5 (IQR 4-8) drugs and a 
median of 10 (IQR 6-28) possible drug pairs were identified. The number of drugs did 
not differ between male and female patients (p=0.76). 
 
Potential drug interactions in general 
The analysis of the medication histories yielded a total of 961 potential drug 
interactions (9.1% of 10,556 possible drug pairs), affecting 375 (62.5%) patients. Of 
those, 413 (43.0%) were classified as minor, 538 (56.0%) as moderate, and 10 
(1.0%) as severe. These potential drug interactions were described in 151 separate 
monographs of the drug interaction database Pharmavista®. Per patient, a median of 
1 (IQR 0-2) potential drug interaction was found. Most prevalent drug classes 
involved were drugs affecting the cardiovascular system (30.8%), the nervous 
system (17.6%), the alimentary tract and metabolism (15.4%), and the 
musculoskeletal system (15.0%). Patients with one or more potential drug interaction 
were treated with significantly more drugs than those without (6 versus 4; p<0.001).  
Of the 961 potential drug interactions detected in the medication history, 174 (18.1%) 
were interactions between drugs previously picked up by the patient at a prior visit at 
the pharmacy. Thus, the remaining 787 (81.9%) potential drug interactions were 
detected upon issuing a new or a repeat prescription. 
 
Frequency and nature of drug interaction alerts 
Individual configuration of the drug interaction alert systems in the 15 community 
pharmacies generated a total of 656 drug interaction alerts. Of those, 146 alerts were 
irrelevant due to multiple alerting for the same drug interaction (N=103; 69.9%) or 
due to alerting of drug combinations of which one drug was no longer taken (N=43; 
30.1%). Thus, out of 787 potential drug interactions caused by a new or repeat  
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prescription, 510 (64.8%) generated a relevant alert affecting 312 (52%) patients. 
The remaining 277 (35.2%) potential drug interactions were systematically 
overridden because of the default configuration of the drug interaction alert systems 
which flagged only distinct categories of potential drug interactions (Figure 2). In four 
of the 15 community pharmacies, the system was set to flag only severe, in 6 to flag 
severe or moderate, and in 5 to flag severe, moderate or minor potential drug 
interactions. Depending on these settings, the median number of alerts per pharmacy 
and per 40 patient visits increased from 0.5 (IQR 0-1) when only severe interactions 
were flagged, to 40 (IQR 35-48) when severe or moderate, and to 76 (IQR 73-91) 
when severe, moderate or minor potential drug interactions were flagged. Overall, 
the median number of alerts per pharmacy and per 40 patient visits was 43 (IQR 2-
73).  
 
Of 787 potential drug interactions, 256 (32.5%) emerged from a new prescription and 
were observed for the first time. Of those, 147 (57.4%) generated an alert and 109 
(42.6%) were overridden because of the default software setting. The time period a 
patients’ past medication history was screened for potential drug interactions can 
also be programmed by the pharmacy. The median number of days set as default 
was 100 (IQR 90-120 days). In pharmacies with a longer prior observation period (≥ 
100 days; N=7), the number of irrelevant alerts was statistically significantly higher 
compared to those with a prior screening period below 100 days (11.5 versus 4; 
p=0.001). The majority (369, 72.4%) of the 510 potential drug interactions causing 
alerts were the result of a prescription by the same physician, and 261 (51.2%) were 
detected on the same prescription. 
Table 1 displays characteristics and pharmacist’s management of drug interaction 
alerts generated by the 10 most prevalent of 787 potential drug interactions detected 
on new or repeat prescriptions.  
 
Management of drug interaction alerts in community pharmacies 
The handling of drug interaction alerts by community pharmacists is displayed in 
Figure 2. Pharmacists reported that 289 of 510 alerts (36.7%) were overridden 
without checking them (Figure 2). When the pharmacist took care of the prescription 
him- or herself (as opposed to having a pharmacy technician taking care of it), 
significantly fewer drug interaction alerts were overridden (Table 2) (410 [80.4%] of 
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potential drug interactions generating alerts were only double checked by the 
pharmacist, but the prescription was taken care of by a pharmacy technician in the 
pharmacy). 
Pharmacists stated that 87 (11.1%) alerts of potential drug interactions were 
analysed in more detail by consulting literature, contacting the prescribing physician 
or discussing the issue with the patient (Figure 2). The main reasons for exploring a 
drug interaction in more detail were higher severity (severe or moderate) of the 
potential drug interaction, or the detection of a potential drug interaction for the first 
time (Table 3). Out of 87 alerts which were explored in more detail, 55 (63.2%) 
prompted an intervention (e.g. close monitoring of the therapy, adjustment of dose or 
ingestion time, termination of a therapy or switching to an alternative therapy) (Figure 
2).  
All severe potential drug interactions (N=10) generated an alert and all caused an 
intervention. These were the combination of a nitrate and a phosphodiesterase-5 
inhibitor (N=3), a monoamono oxidase inhibitor and a sympathomimetic drug (N=1), 
the combination of an HMG-CoA reductase inhibitor and a macrolid antibiotic (N=2), 
an oral anticoagulant and a salicylate (N=3), or combining potassium with a 
potassium-sparing diuretic (N=1).  
According to the pharmacists, they decided to inform 34 (15.9%) of 204 patients with 
drug interaction alerts about the potential risk of 42 (5.3%) of 787 potential drug 
interactions.  
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Discussion 
We found a substantial proportion (71.9%) of overriding potential drug interactions in 
daily pharmacy practice. In our analysis we distinguished between systematic 
override of potential drug interactions via configuration of the drug interaction alert 
systems (35.2%), and overriding potential drug interactions generated by computer 
alerts without taking further action (36.7%). Previous studies exploring the 
management of drug interaction alerts reported even higher frequencies of overriding 
alerts [7-9].  
 
In our study, pharmacies were free to configure the system as they liked. Thus, they 
decided to set the default for alerts for various severities of potential drug 
interactions, and they could choose the period of previous medication history in a 
patient record covered by the drug interaction check. We set as a standard a time 
period of 3 months because most drug packages are designed to cover a therapy of 
3 months, and therefore potential drug interactions during chronic therapies should 
be identified. We defined any potential drug interaction described in the drug 
interaction database (severe, moderate or minor) as relevant for drug interaction 
check without any filtering. The same drug interaction database was used in all study 
pharmacies. Thus, the frequency of detecting and overriding drug interaction alerts 
depends on all these parameters, and they are rarely comparable. In our study we 
found by on-site observation a 56.7% override of drug interaction alerts, as compared 
to self-reported override of 14% in a previous study with similar pharmacies using the 
same drug interaction database [11]. 
 
To reduce the frequency of clinically irrelevant interaction alerts, most pharmacies in 
our study set their systems to flag only potential drug interactions of high severity. 
Consequently, they tolerated the computerised override of 35.2% of potential drug 
interactions of only minor or even both, moderate or minor severity, including 109 
first-time potential drug interactions. Bergk and co-workers [15] showed that the 
frequency of alerts could be reduced by 28% when filtering the fraction of minor and 
unspecified potential drug interactions. A panel of pharmacists concluded that the 
sensitivity of the computer systems should be adjustable [8]. However, there is no 
good data basis to support an arbitrary delineation of drug interaction alerts, and  
 
Project D: Management of drug interaction alerts 
 112
there is a risk of patients being harmed by drug interactions rated as being low risk 
drug interaction [16]. In a study of potential drug interactions with transplant 
medications, it was noted that, if the system was set to alert only for contraindicated 
pairs, 90% of clinically significant interactions would be missed [17]. Therefore, the 
override of drug interaction alerts of moderate or minor severity may be a 
questionable step. 
 
Various reasons may contribute to the remarkable proportion of overridden 
interaction alerts. A main reason for overriding alerts may be that pharmacists are 
desensitised to check drug interaction alerts because they are inundated with too 
many inappropriate or even invalid alerts [6, 18]. Hansten and Horn referred to this 
effect as ‘alert fatigue’ [19]. On the other hand, community pharmacists considered 
drug interaction alerts to be useful and did not state that a high alert frequency 
decreases the ability to spot clinically relevant drug interactions [20].  
This study further suggest that pharmacists were more likely to override potential 
drug interactions if a technician handled the prescription and the pharmacist only 
double-checked it for control purposes, as opposed to handling the prescription him 
or herself. In Switzerland, the pharmacists on duty is required to check all drugs 
dispensed on prescription by a technician, but this findings indicates that the 
pharmacist may still be less aware of a possible interaction alert on computer if 
someone else handles the prescription. 
 
In our study, only a small part of the interaction alerts were flagged for the first time. 
A high rate (71.2 %) of alerts was probably useless. They were caused by the 
renewal of drug combinations that might already have been checked before, by 
invalid alerts due to previous discontinuation of interacting drugs, or by multiple alerts 
for the same potential drug interaction (Figure 2). The high frequency of alerts 
caused by renewals was already reported by previous studies [7, 8]. Hence, 
intelligent computer systems allowing the documentation and thereby specific 
inactivation of previously evaluated drug interaction alerts on an individual patient 
record level to reduce or eliminate duplication alerts would be desirable [8]. Indeed, 
Peng and co-workers [21] reported that sophisticated filters (e.g. assessment of time 
overlapping of drug therapies, of duration of drug therapy, and of total drug dose) 
could reduce the incidence of potential drug interaction alerts by 71% and in 
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combination with pharmacists’ review even by 94%. Our results further underline the 
need for such sophisticated software filters. 
 
Another reason for overriding drug interaction alerts without further evaluation might 
be the attitude of pharmacists who may consider most drug interactions to be 
clinically irrelevant for their patients based on personal experience. Indeed, although 
in theory potential drug interactions are common, only few have serious clinical 
consequences [22-24]. Furthermore, the computer systems produce a high number 
of alerts, but they do in fact overestimate the risk of drug interactions since by far not 
all alerts would lead to clinical consequences in all patients [25]. Thus, as revealed in 
this study, pharmacists tend to focus on potentially relevant potential drug 
interactions according to the classification provided by the drug interaction database. 
A similar reasoning was reported by physicians who admitted to override drug 
interaction alerts; 98% believed that the potential drug interaction was not serious, 
and 87% thought that it was not relevant to their patient [10]. However, decision 
based on personal experience alone may not be good enough to manage risks, 
because the number of observations made by an individual heath care provider is not 
sufficient to predict the likelihood of an individual patient to suffer from a drug 
interaction [26]. 
 
A majority (61%) of 221 alerts not overridden by pharmacists did not lead to specific 
action, and pharmacists often did not further evaluate an alert because it was already 
evaluated in the past (Figure 2). However, when they analysed an alert more 
precisely by consultation of the literature, by contacting the prescribing physician or 
by discussing the problem with the patient, an intervention frequently occurred. 
Consequently, both the decision whether a more in depth analysis of an alert is 
required, as well the decision what to do about it, are important intellectual services 
provided by pharmacists. Further studies are needed to investigate if these decisions 
and interventions were adequate and whether they had indeed beneficial clinical 
consequences for the patients. 
The majority of potential drug interactions alerts were caused by a prescription 
issued by the same physician (72.4%), and in 52.4% of alerts the potentially drugs 
were on the same prescription. The likelihood of overriding interaction alerts or of 
evaluating them in more detail was neither associated with drugs being prescribed by 
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separate physicians (versus same physician), nor with drugs being prescribed on 
separate prescriptions. However, a possible approach for community pharmacies to 
reduce the workload induced by potentially irrelevant alerts may be to focus only on 
patients getting drugs prescribed by different prescribers. Tamblyn and co-workers 
[27] revealed that patients who had a single primary-care physician were less likely to 
be prescribed drugs potentially causing a drug interaction compared with patients 
with more than one prescriber. 
Of the potential drug interactions classified as severe, none was overridden by the 
pharmacists and all were managed by intervention in our study. Thus, the 
classification of a potential drug interaction as being potentially severe is a strong 
predictor for a subsequent work-up of the alert by the pharmacist. This emphasised 
the need for a drug interaction classification used by commercially available 
databases which is indeed based on pharmacologically correct, timely and 
appropriate information. Most potential drug interactions do not have to be regarded 
as absolute contraindications but can be managed adequately e.g. by close 
monitoring, dose adjustment or a coordinated sequence of drug administration (15). 
However, most of these manageable potential drug interactions are classified as 
‘moderate’ or ‘minor’ in drug interaction databases and are therefore often ignored a 
priori by default. Computer programs producing interaction alerts and at the same 
time providing also management options to health care providers may be highly 
welcome [6, 28]. 
 
Several strengths and limitations of this study merit further discussion. In our study 
we have chosen to conduct an on-site observation using trained students shortly 
before getting their pharmacy diploma. Even though the data prescriptions issued 
and the number and nature of all potential drug interactions in the medication history 
with all flagged alerts are likely to be valid, and even though structured interviews 
with the pharmacist on duty were conducted on the same day to reliably reflect the 
management and overriding habits of such alerts, we still rely on subjective data from 
interviews. There is a possibility of some sort of bias because the student and the 
pharmacist on duty are part of the same pharmacy team. However, this was not 
considered to be a major problem, according to a self-evaluation of the students. The 
study was conducted in the German-speaking part of Switzerland and may only 
represent the health care situation in this region. However, a main reason to 
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extrapolate the findings to other European health care systems is the fact that the 
drug interaction alert systems in community pharmacies from all study pharmacies is 
the same as used in all other parts of German-speaking countries (Switzerland, 
Germany, and Austria). Another limitation of this study is the relatively small sample 
sise of 15 community pharmacies. Therefore, the study may in theory reflect a 
chance finding not generalisable to other populations. Furthermore, we did not 
assess clinical outcomes on a patient level, and we don’t know whether patients 
actually suffered from clinical consequences of drug interactions or whether drug 
interactions were prevented by pharmacists’ interventions. Another point to keep in 
mind is that, even though most community pharmacies are adequately equipped with 
drug interaction alert systems, this often does not apply to over-the-counter drug use. 
There is a potential for drug interactions with over-the-counter medication, but few 
pharmacies record over-the-counter drug use in electronic patient records. Efforts to 
increase the identification and awareness of potential drug interactions in this area 
may be needed [29]. 
 
In summary, this study indicates that overriding alerts for potential drug interactions 
of minor to moderate severity is quite frequent. Pharmacists sometimes override drug 
interaction alerts without further evaluation either by ignoring them after an alert 
came up, or by setting their systems to flag only potential drug interactions of high 
severity. Nevertheless, although drug interaction alert systems have several 
limitations, they may help to improve drug safety and to provide information for an 
adequate management of potential drug interactions by community pharmacists. 
Improved systems are required with higher sensitivity and specificity and lower 
numbers of inappropriate alerts. As long as no more sophisticated filters are 
available, it is important to avoid the override of severe potential drug interactions, a 
goal that seems to be largely accomplished based on the findings of this study. 
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Tables 
Table 1: The 10 most prevalent potential drug interactions detected on new or refill prescriptions of regular pharmacy customers and management of 
drug interaction alerts by community pharmacists. 
Drug combination Severity Potential adverse effect  Patients  
[N (%)]; 
(N=600) 
Potential 
drug 
interactions1 
[N (%)]; 
(N=787) 
Alerts  
[N (%)]; 
(N=510) 
Override2 
[N (%)]; 
(N=289) 
Precise 
Analysis3  
[N (%)]; 
(N=87) 
Intervention4 
[N (%)]; 
(N=55) 
Diuretic (loop or thiazide) + 
NSAID 
moderate Decreased diuretic and 
antihypertensive effectiveness 
45 (7.5) 52 (6.6) 42 (8.2) 20 (6.9) 5 (5.7) 1 (1.8) 
ACEI + diuretic (loop or 
thiazide) 
minor Postural hypotension 44 (7.3) 50 (6.4) 36 (7.1) 26 (9) 3 (3.4) 1 (1.8) 
Antidiabetes agent + ACEI minor Hypoglycemia 37 (6.2) 49 (6.2) 42 (8.2) 28 (9.7) 4 (4.6) 1 (1.8) 
ACEI + NSAID moderate Decreased antihypertensive 
effectiveness and/or renal function 
32 (5.3) 34 (4.3) 25 (4.9) 12 (4.2) 4 (4.6) 2 (3.6) 
NSAID + glucocorticoid moderate Gastro intestinal ulcers and/or 
bleedings 
25 (4.2) 28 (3.6) 25 (4.9) 15 (5.2) 3 (3.4) 0 (0) 
Antidiabetes agent + thiazide 
diuretic or analogue  
minor Decreased antihyperglycemic 
effectiveness 
22 (3.7) 33 (4.2) 24 (4.7) 18 (6.2) 2 (2.3) 1 (1.8) 
Beta blocker + NSAID moderate Decreased antihypertensive 
effectiveness 
21 (3.5) 24 (3.1) 20 (3.9) 11 (3.8) 3 (3.4) 1 (1.8) 
Biphosphonates + polyvalent 
cations5 
moderate Decreased biphosphonate 
effectiveness 
20 (3.3) 28 (3.6) 20 (3.9) 8 (2.8) 6 (6.9) 6 (10.9) 
Neuroleptic agent + SRI moderate Increased plasma levels or QT-time 
prolongation 
20 (3.3) 20 (2.5) 13 (2.5) 7 (2.4) 4 (4.6) 3 (5.5) 
Antidiabetes agent + beta 
blocker 
minor Decreased diabetic control 18 (3.0) 25 (3.2) 18 (3.5) 14 (4.8) 3 (3.4) 2 (3.6) 
1In one patient the same potential drug interaction could be de detected several times, e.g. when treated with two antidiabetic agents metformin and glimepiride + 
ACEI 
2Override by pharmacist without any evaluation = The drug interaction was neither mentioned nor considered during the fulfilment of the prescription 
3Precise analysis= Consultation of e.g., literature, prescriber(s), or patient himself 
4Intervention = E.g., close monitoring, adjustment of dose or ingestion time, stop of therapy, or alternative therapy 
5Polyvalent cations= Drugs containing e.g. aluminium, calcium, magnesium, iron, etc. (E.g., antacids, mineral nutrients) 
NSAID = non-steroidal anti-inflammatory drug; ACEI = angiotensine converting enzyme inhibitor; SRI = serotonin reuptake inhibitor 
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Table 2: Determinants associated with the override (N=289) of drug interaction alerts (N=510) in 
community pharmacies. 
 
Determinant N (%) P-value Adjusted OR 95% CI 
Gender (female) 162 (56.1) 0.749 0.94 0.66-1.35 
Age (≥ 65 years) 141 (48.8) 0.495 1.13 0.79-1.63 
Fulfilment of prescription by pharmacist himself 48 (16.6) 0.042 0.63 0.40-0.98 
Different prescribers  78 (27.0) 0.722 0.92 0.60-1.43 
Different prescriptions  157 (54.4) 0.710 0.93 0.63-1.37 
Potential severity (severe or moderate) 144 (49.8) 0.067 0.71 0.50-1.02 
Period a patient’s past medication history was 
screened for potential drug interactions (≥100 
days) 
155 (53.6) 0.075 1.39 0.97-1.99 
First time alert  69 (23.9) 0.191 0.76 0.51-1.14 
OR = Odds ratio; CI = Confidence interval 
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Table 3: Determinants associated with the more precise analysis (N=87) of drug interaction 
alerts (N=221) in community pharmacies. 
 
Determinant N (%) P-value Adjusted OR 95% CI 
Gender (female) 49 (56.3) 0.500 0.81 0.44-1.49 
Age (≥65 years) 38 (43.7) 0.797 1.08 0.58-1.98 
Fulfilment of prescription by pharmacist himself 23 (26.4) 0.640 1.18 0.59-2.36 
Different prescribers  28 (32.2) 0.994 1.00 0.49-2.05 
Different prescriptions  54 (62.1) 0.410 1.32 0.68-2.53 
Potential severity (severe or moderate) 67 (77.0) < 0,001 3.34 1.77-6.31 
Period a patient’s past medication history was 
screened for potential drug interactions (≥100 
days) 
43 (49.4) 0.333 1.35 0.74-2.48 
First time alert  42 (48.3) < 0.001 3.76 1.98-7.14 
OR = Odds ratio; CI = Confidence interval 
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Figures 
Figure 1: Question scheme used in the structured interview with pharmacists on duty to 
assess the actions taken due to drug-drug interaction alerts 1:  
 
 
Was the alert considered or mentioned 
during the prescription fulfilment process? 
Yes 
No 
Alert was overridden 
Did the alert trigger a more precise 
analysis? (E.g., consultation of. literature, 
prescriber(s) or patient himself) 
Yes 
Was the prescribed therapy modified?  
(E.g. by close monitoring, adjustment of 
dose or ingestion time, stopped or 
alternative therapy 
No 
Reasons? 
- drug interaction already 
analysed before 
- No time overlap of 
interacting therapies 
- Low severity 
- Monitoring warranted / 
safe patient situation 
- Other reason? 
If the potentially interacting drugs were 
dispensed; was the patient informed? 
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Figure 2: Management of drug interaction alerts assessed in an interview with the pharmacist 
on duty (510 potential drug interaction alerts among 204 patients). 
 
1 Override = The drug interaction was neither mentioned nor considered during fulfilment of the 
prescription 
2 Precise analysis = Consultation of e.g., literature, prescriber(s), or patient himself 
3 Intervention = E.g., close monitoring, adjustment of dose or ingestion time, stop of therapy, or 
alternative therapy 
 
 
 
510 drug interaction alerts (64.8%) 
289 (36.7%) Overriden1 by 
pharmacists without evaluation 
134 (17%) 
No precise analysis2 
87 (11.1%) 
Precise analysis2 
85 (10.8%) Already 
evaluated in the past 
32 (4.1%)  
Low severity 
17 (2.2%)  
Safe patient situation / 
Monitoring warranted 
55 (7%) Intervention3 
787 potential drug interactions (100%) 
277 (35.2%) Overriden1 because 
of pharmacies’ software settings 
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7 General discussion, conclusions and outlook 
7.1 General discussion 
In the present thesis different aspects of the management of potential drug 
interactions in the process of pharmaceutical care were evaluated. 
 
In project A we researched additive effects of different risk factors on the 
development of hyperkalaemia which can lead to life-threatening adverse effects. 
Hospitalised patients with multiple risk factors including risk drugs (potassium 
supplements, potassium-sparing diuretics, ACEI or ARB) and comorbidities (severe 
renal impairment, diabetes mellitus) developed faster and higher hyperkaelemic 
serum potassium levels (≥ 5.0 mmol/L) than patients without or only few of these 
risks. Furthermore, the study showed that the use of risk drugs significantly increased 
during hospital stay. Two other studies, also conducted at the University Hospital 
Basel, revealed that the number of potential drug interactions increased significantly 
during hospital stay whereas the combinations between ACEI + potassium-sparing 
diuretics, ACEI + potassium supplements, and potassium supplements + potassium-
sparing diuretics were among the most prevalent.6, 18 Hyperkalaemia is a common 
electrolyte disturbance in hospitalised patients despite close monitoring of potassium 
levels and renal function. But, similar to other studies86, 87 only few patients 
developed severe hyperkalaemia (>6.5 mmol/L). The situation might be different in 
outpatients because less intense monitoring could result in an increased risk of fatal 
outcomes. Juurlink et al.88 revealed increased rates of hyperkalaemia-induced 
hospitalisations after the publication of the RALES study, which provoked a wide use 
of spironolactone combined with ACEI without caution. Patients with multiple risk 
factors for hyperkalaemia should be closely monitored and a rapid change in 
laboratory values should alert health care providers to action by identifying and 
possibly removing risk drugs. With regard to medical and pharmaceutical care, health 
care professionals prescribing and dispensing such risk drugs must consider both, 
potential drug interactions and patient-related risk factors.89, 90 In ambulatory settings 
the linkage between laboratory and pharmacy systems would be a promising 
approach for a closer monitoring of drug therapies.91  
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Project B focussed on selected potential drug interactions of different clinical 
relevance between POMs and OTC drugs pharmacy customers purchased for self-
medication. Even though, only a selection of potential drug interactions was 
investigated, we observed a high prevalence of potential drug interactions between 
POMs and self-medication drugs. In particular among regular customers treated with 
selected POMs, the prevalence of potential drug interactions was high. Whereas 
passer-by customers seldom reported to take POMs potentially interacting with the 
OTC-drugs they purchased. Therefore, to focus on regular pharmacy customers 
might be a helpful strategy to identify and manage potential drug interactions with 
self-medication. Although the impact of account cards for purchased self-medication 
drugs could not have been shown, this might be a promising approach in community 
pharmacies to improve drug safety by assessing entire medications profiles. This 
service is recent and currently only few customers are covered. Wider 
implementation of this service would be useful. A precondition is the customer’s 
acceptance of surveillance by his pharmacy. Therefore, customers have to be 
motivated to participate more fully in their healthcare.92 Establishing a caring 
relationship with the patient involving information provision and communication is a 
basic step of the pharmaceutical care process93. Thereby pharmacists can play an 
important role in reducing the risk of some drug interactions. Although most regular 
customers reported an infrequent intake of their OTC drugs, self-medication still 
presents a substantial risk for drug interactions. In the present project only 46.8% of 
regular customers were aware about potential drug interactions of their POM with 
self-medication and of them 47.3% admitted to be informed by the physician and 
25.6% by the pharmacist. The level of information varied among customers with 
different drug therapies and the awareness was significantly higher for ‘severe’ 
potential drug interactions.  
Potential drug interactions between POM and OTC drugs for self-medication are 
widespread. Efforts for an improved vigilance and an increase of awareness are 
needed. New approaches such as account cards to assess regular customers OTC 
drugs can be promising. Other actions include a better labeling of risky OTC drugs 
and the need to query patients’ self-medication.94  
 
Project C aimed to assess how pharmacists deal with drug interactions in daily 
practice, which information sources they use and wish to have, and how their 
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requirements relate to those expressed by general practitioners. Pharmacists 
admitted that computerised drug interaction alert systems supporting their fulfilment 
of prescriptions lacks sensitivity and specificity in identification of patients at risk 
while producing a high rate of possibly clinically irrelevant and invalid alerts. Such 
deficiencies of computerised drug interaction surveillance systems have already 
been shown in other countries.71, 82 There is insufficient information to determine 
whether these systems are actually helpful in the community pharmacy settings.70 
Despite deficiencies of the drug interaction alert systems pharmacists admitted that 
they consider the majority of the provided alerts and override only a small amount 
(14%) of them.  
It is not enough information for the health care provider to be informed, that two 
drugs may interact. It is also important to have access to information on measures 
that can be taken to reduce the likelihood of an adverse outcome.58 In the present 
study pharmacists reported to be unsatisfied with the information about non-
interacting alternative therapies and the specific advice for dose adjustment in the 
drug interaction information sources they use. General practitioners expressed the 
same criticism.63 With regard to the content of future drug interaction information 
sources community pharmacists and general practitioners expressed very different 
expectations with the largest difference seen in the valuation of information 
components on advice for dose adjustment and non-interacting alternatives which 
were less essential for community pharmacists. This result reflects the different 
situations and needs of the two professions in daily practice. Substantial 
improvement of drug interaction software systems is thus required at least in two 
important aspects, the suppression of inappropriate alerts and the tailoring to the 
needs of the user. 
 
The findings in Project C launched a discussion on optimisation of the currently used 
drug interaction softwares and the classification of the drug interaction database. The 
AKA (Medicines Commission of Swiss Pharmacists) debated about the need of a 
new management-based classification of potential drug interactions according to 
ORCA58 (Table 3). An adjustment of the classification was already effected by other 
database providers: The US-database by Thompson Micormedex™59 newly 
implemented in 2004 a fourth class of contraindicated next to major, moderate and 
minor drug combinations and the French Health Products Safety Agency (afssaps) 
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introduced in 2005 the new ‘Thesaurus des interactions medicamenteuses’ a new 
management-based classification with four categories (contraindication, combination 
disadvised, caution of use, intake possible) similar to ORCA58 (Table 3). Table 5 
displays the classification recommendation of AKA. When adopting the classification 
according to ORCA most drug interaction monographs will be disposed in category III 
‘Monitoring respectively adjustment of the therapy necessary’. Therefore, the 
suggestion is to subdivide this category considering that some drug interactions only 
harm predisposed patients. This approach would simplify the management because 
the user obtains direct information about patient related risk factors. Future 
approaches e.g. electronic patient-held record cards containing information of 
comorbidities or pharmacogenetics, could directly be linked with the drug interaction 
database. Furthermore, the AKA suggested to consider the management options in 
community pharmacies and to provide specific information to community pharmacies 
that potential drug interactions can be managed under their own direction or that the 
consultation of the prescriber is needed. This information would reduce the workload 
of analysing potential drug interactions in the prescription fulfilment process. For 
example, the potential drug interaction between antacids and quinolones can easily 
be managed in community pharmacies by giving the quinolone 2 hours before or 6 
hours after the antacid.  
The AKA recommends to include categories I to III in the drug interaction check in 
community pharmacies. Category IV should contain clinically irrelevant potential drug 
interactions of minor or unspecified clinical relevance that do not demand any 
management action. Category V contains drug pairs with evidence that no interaction 
between two drugs exists (Table 5).  
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Table 5: Recommendations of the Medicines Commission of Swiss Pharmacists (AKA) for a 
new management-based classification of potential drug interactions in community pharmacies 
according to the operational classification by Hansten, Horn and Hazlet58. 
 
Categories Characterisation Management  
I: Contraindicated  The risk of the combination always 
outweighs benefit 
 
- Medication error - Avoid and if 
possible consider alternative after 
consultation of prescriber(s) 
II: Usually 
contraindicated  
Under special circumstances the 
benefit of the combination 
outweighs the risk 
 
- Use only after consultation of 
prescriber(s) 
- If possible consider alternative  
- Monitoring and/or adjustment of the 
therapy 
- Inform patient 
IIIa: Minimise risk 
by adjustment or 
monitoring of the 
therapy -  
IIIb: Minimise risk 
only in 
predisposed 
patients  
The benefit of the combination of 
therapy outweighs the risk 
 
- Use after consultation of 
prescriber(s) or in pharmacists’ 
direction 
1. If possible consider alternative 
(only after consultation of 
prescriber(s)) 
2. Monitoring and/or adjustment of 
the therapy (If possible in 
pharmacists’ direction) 
3. Inform patient 
IV: No special 
precautions  
Risk of adverse outcome appears 
small 
- Use recommended 
- Eventually inform patient 
V: Ignore Evidence suggests that the drugs 
do not interact 
- Ignore 
 
In Project D we focussed on community pharmacies management of drug interaction 
alerts in regular customers. Pharmacists overrode 71% of drug interactions without 
any evaluation either by ignoring them or by setting their systems to flag only 
potential drug interactions of high severity. This is a much higher percentage than 
that reported by the pharmacists in project C (14%). Pharmacists were sensitised to 
analyse first-time alerts and potential drug interactions of high severity. Most alerts 
were caused by repeated drug combinations and might therefore already have been 
verified. This result has already been found in studies in community pharmacies in 
other countries.77, 82 Hence, substantial improvement of sensitivity and specificity of 
drug interaction alert systems is required. A more sophisticated approach for drug 
interaction alert systems to focus only on new prescriptions would significantly 
reduce the number of alerts and consequentially the inundation with irrelevant alerts.  
When pharmacists limit their drug interaction alerts systems to a subset of the total 
database, they are assuming that none of the ignored interactions will cause an 
adverse outcome in a patient.95 A lot of pharmacists may believe that most drug 
interactions are clinically irrelevant for their patients according to the experience they 
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gained over years. But there would be a medicolegal risk if a patient is harmed by a 
‘low risk’ drug interaction.96 Peng et al.97 revealed that some sophisticated filters (e.g. 
regarding drugs dose and time overlap of the therapies) would reduce the amount of 
potential drug interactions by 71% and together with pharmacists review by > 94%.  
Use of sophisticated filters would significantly reduce the override. While such 
improvements are essential, no computer program can replace pharmacists’ 
informed evaluation to recognise the factors that alter a patient’s risk for an adverse 
event and to consider the risk against the benefit of administering the drugs. 
Therefore, pharmacists should be sensitised to manage drug interaction alerts 
adequately. 
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7.2 Conclusions 
In conclusion this thesis shows that: 
 
• Project A revealed that patients with risk factors for hyperkalaemia (renal 
impairment, diabetes mellitus) should be closely monitored when adding 
combinations of risk drugs for hyperkalaemia (potassium supplement, 
potassium-sparing diuretics, ACEI or ARB). And, a rapid change in laboratory 
values should alert health care providers to action by identifying and possibly 
removing risk drugs.  
 
• OTC-drugs purchased for self-medication may often not be considered in the 
management of potential drug interactions. Freely available, their use is often 
perceived as safe by customers. Project B shows that potential drug 
interactions between POM and OTC drugs for self-medication are 
widespread. Efforts for an improved vigilance and an increase of patient 
awareness are needed. New approaches like patient-held account cards 
would enable to document self-medication in the medication history of a 
patient. Thus, they would be covered by the automatic drug interaction 
check. 
 
• In Project C pharmacists admitted that computer-assisted drug interaction 
surveillance in community pharmacies lacks sensitivity and specificity while 
producing a high rate of invalid alerts. The study also showed that the 
information needs of community pharmacies differed considerably compared 
to those of general practitioners. Hence, substantial improvement of drug 
interaction software systems is required at least in two important aspects, the 
suppression of inappropriate alerts and the tailoring to the needs of the user. 
 
• In project D we revealed that pharmacists override many drug interaction 
alerts without any evaluation either by ignoring them or by setting their 
systems to flag only potential drug interactions of high severity. They are 
sensitised to analyse first-time alerts and potential drug interactions of high 
severity. The results show that focusing on new prescriptions would 
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significantly reduce the number of alerts. Substantial improvement of 
computer-assisted drug interaction surveillance is required. But finally no 
computer program can replace the informed evaluation of potential drug 
interactions and therefore pharmacists should be sensitised to manage the 
alerts adequately. 
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7.3 Outlook 
Figure 5: Possible approaches to darn the present gaps in defenses on prescriber’s, 
pharmacist’s, patient’s or carer’s level to prevent adverse drug reactions resulting from a drug 
interaction according to the Swiss cheese model by Reason56. 
 
 
 
Recapitulating the present thesis, numerous problems in the management of 
potential drug interactions were revealed. These gaps in defense have to be darned 
to avoid adverse drug reactions resulting from drug interactions (Figure 5). Therefore, 
the impact of new approaches should be evaluated in future projects:  
 
• An important factor for an accurate management of potential drug interactions 
is the knowledge of potential drug interactions by health care providers. 
Pharmacists often override drug interaction alerts because they are 
desensitised to manage them. Currie et al.98 showed that training programs 
proved to be an effective way to increase the number of DRPs including 
potential drug interactions identified and addressed by pharmacists. 
Therefore, knowledge and skills of the pharmacist in managing drug 
interactions, including how to judge the risk of a drug interaction, should be 
improved through basic and continuing education. In most community 
pharmacies drug interaction alerts will be noticed first by technicians. They 
should be instructed and supervised on how to judge and, if possible, how to 
manage these alerts.2 
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• For health care providers it is important to acquire directly information on 
measures that can be taken to reduce the likelihood of an adverse outcome. 
Pharmacists are unsatisfied with the current information contents their drug 
interaction information sources provide (project C). A new management-
based classification based on ORCA58 should be implemented in the 
currently used drug interaction database (Pharmavista®61). Pharmacists 
assume that none of the ignored interactions will cause an adverse outcome 
when checking only potential drug interactions of high severity. Significant 
drug interactions might be missed and medicolegal risk exists if a patient is 
harmed by a low risk interaction.95 Therefore, the current classes of potential 
drug interactions should be reviewed, compared with standard information 
sources and classified according to their management options (Table 5). 
  
• Project C and D revealed that pharmacists are inundated with invalid alerts 
(multiple alerts for the same potential drug interaction or for combinations of 
which one drug already had been stopped) and alerts for renewal 
prescriptions that might already have been approved. Project D showed that in 
regular customers only 32.5% of potential drug interactions occurred for the 
first time. Therefore, before setting pharmacies computer software to flag only 
potential drug interactions of high severity it would be obvious to improve drug 
interaction software ability to recognise first time alerts and to filter already 
evaluated potential drug interactions. Furthermore, with this new approach the 
stop of interacting drug combinations could be identified. This is important for 
several potentially interacting drugs. For example the dose of digoxin has to 
be readapted when the therapy with a p-Glycoprotein Inhibitor like itraconazol 
is discontinued. Current computer software in community pharmacies needs 
substantial improvement. Adding new sophisticated computer settings 
would lead to a re-engineering of the prescription fulfilment process. 
Therefore, community pharmacies have to debate with computer software 
providers to achieve desired improvements of their computer software. 
 
• The communication between involved institutions in ambulatory care, 
hospital and perihospital institutions is a critical issue. The access to clinical 
relevant informations (complete medication, patient history and laboratory 
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data) has still to be optimised. New information and communication 
technologies would facilitate the surveillance of drug-related problems 
including those caused by drug interactions. New approaches like electronic 
prescribing and data management by computer health care networks are 
planned or are partially implemented. Their impact in pharmaceutical care and 
particularly in the management of potential drug interactions has still to be 
investigated.  
For the management of potential drug interactions it is important to be 
informed about the medication history, patient-related risk factors, patients’ 
laboratory data and patients’ self-medication. Electronic patient-held records 
might improve the current situation. With patients electronic insurance card a 
valuable instrument to record these data would be available. 
Overall, recent developments in e-health to support health decision-making 
processes may have multiple potential benefits. This asks for intensified 
research, including the impact on pharmaceutical care and in particular on the 
prevention of drug related problems. 
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